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RESUMEN 
 
 
 
 
RESUMEN 
En este trabajo hemos analizado el mecanismo de acción tumorogénica de los ligandos 
del Receptor Activado por Proliferadores Peroxisomales γ (PPARγ) 15-deoxi-Δ12-14-
PGJ2 (15d-PGJ2), rosiglitazona y pioglitazona en células humanas de cáncer de mama. 
Nuestros datos muestran que el tratamiento con estos compuestos reduce la viabilidad, 
inhibe la proliferación y favorece la apoptosis en varias líneas celulares de carcinoma 
mamario, y atribuyen por vez primera efectos similares a los miembros de la familia de 
compuestos denominados tiadiazolidinonas (TDZDs). Además, hemos determinado que 
algunos de sus efectos son llevados a cabo, al menos en el caso del agonista natural 15d-
PGJ2, por defosforilación de ErbB2 y ErbB3 a través de un incremento en la actividad 
fosfatasa de la fosfatasa 1 con dominios de homología a Src (SHP-1). Por otro lado, 
demostramos que 15d-PGJ2 es responsable de inducir en células de cáncer de mama 
parada de ciclo celular en la fase G2/M así como una desestructuración significativa de 
la red de microtúbulos mediante su unión directa a tubulina. También mostramos los 
efectos antineoplásicos de los ligandos de PPARγ en el crecimiento y la auto-
renovación de las células madre humanas de cáncer de mama. Por último, hemos 
evaluado la fiabilidad del perfil de expresión CD44+/CD24-/bajo como marcador de 
células madre humanas de cáncer de mama y de la “side population” como modelo de 
las mismas. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
SUMMARY 
 
 
 
 
SUMMARY  
In this work we have analyzed the antitumorigenic mechanism of action of the 
Peroxisome Proliferator-Activated Receptor γ (PPARγ) ligands 15-deoxi-Δ12-14-PGJ2 
(15d-PGJ2), rosiglitazone and pioglitazone on human breast cancer cells. Our data show 
that treatment with these compounds reduces cell viability, induces inhibition of 
proliferation and promotes apoptosis in several breast carcinoma cell lines, and attribute 
for the first time similar effects to members of the thiadiazolidinones (TDZDs) family 
of compounds. In addition, we determined that some of their effects are exerted, at least 
in the case of the natural agonist 15d-PGJ2, through an increase in the phosphatase 
activity of Src-Homology-2 domain-containing phosphatase 1 (SHP-1), by 
dephosphorylation of ErbB2 and ErbB3. In addition, we show that 15d-PGJ2 is 
responsible for inducing cell cycle arrest of breast cancer cells in the G2/M phase of the 
cell cycle and a significant dysruption of the microtubule network following its direct 
binding to tubulin. Furthermore, we show antineoplastic effects of PPARγ ligands on 
growth and self-renewal of human breast cancer stem cells. Finally, we have evaluated 
the reliability of CD44+/CD24-/low expression profile as a marker and of the ‘side 
population’ as a working model for human breast cancer stem cells.  
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ABBREVIATIONS 
 
15d-PGJ2  15-deoxi-Δ12,14-PGJ2 
ABCG2  ATP-Binding Cassette, Subfamily G Member 2 
AF-1    Activation Function-1 
ALDH  Aldehyde dehydrogenase 
aP2   Adipocyte fatty acid binding protein 
ATP    Adenosine triphosphate   
APC   Allophycocyanin 
BDP1   Brain-Derived Phosphatase-1   
bFGF   Basic Fibroblast Growth Factor 
BrdU   5-Bromo-2-deoxy-uridine 
BSA   Bovin Serum Albumin 
CBP-1   CREB-binding protein-1 
COX    Cyclooxygenase 
DAPI   4,6-diamidino-2-phenylindole 
DEP1    Density-Enhanced-Phosphatase 1 
DNA   Deoxyribonucleic acid 
DR1    Direct Repeat 1 
DTT   Dithiotreitol 
ECL   Enhanced Chemoluminiscence 
EDTA   Ethylenediaminetetraacetic acid 
EGF    Epidermal Growth Factor  
EGFP   Enhanced Green Fluorescent Protein 
EGFR   Epidermal Growth Factor Receptor 
EGTA   Ethyleneglycoltetraacetic acid 
ErbB    Erythroblastic Leukemia Viral Oncogene Homolog 
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FACS   Fluorescence-Activated Cell Sorting 
FBS   Fetal Bovine Serum 
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FTC   Fumitremorgin C 
HPLC   High Performance Liquid Chromatography 
IKK    IKB Kinase 
iNOS    Inducible Nitric Oxide Synthase 
iRNA   Interference RNA 
LPL    Lipoprotein lipase 
MAPK  Mitogen-Activated Protein Kinase 
M-MLV RT  Moloney Murine-Leukaemia Virus Reverse Transcriptase 
MRM   Multiple Reaction Monitoring 
mRNA  Messenger RNA 
MS   Mass spectrometry 
MT   Microtubule 
MTT   3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide 
NCoR1-2  Nuclear Co-Repressors 1-2 
NF-kB   Nuclear Factor-kB 
NRG    Neuregulin 
NSAID   Non-Steroideal Anti-Inflammatory Drug 
PAGE   Polyacrilamide Gel Electrophoresis 
PBS   Phosphate-buffered saline 
PCR                           Polymerase Chain Reaction 
PE                              Phycoeritrin 
PGZ   Pioglitazone 
PI   Propidium Iodide 
PI3K    Phosphatidylinositol 3-kinase   
5 
 
PMSF   Phenylmethylsulphonyl fluoride 
PPAR   Peroxisome Proliferator-Activated Receptor 
PPRE   PPAR Response Element 
PTB    Phosphotyrosine Binding 
PTP    Protein Tyrosine Phosphatase   
Q-PCR  Quantitative PCR 
RIP140  Receptor Interacting Protein 140 
RNA   Ribonucleic acid 
RSG   Rosiglitazone 
RXR   Retinoid X Receptor 
SD   Standard Deviation 
SDS   Sodium Dodecyl Sulfate 
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SHP-1   SH2-domain containing phosphatase-1 
SHP-2   SH2-domain containing phosphatase-2 
SMRT1-2  Silencing Mediator for Retinoid and Thyroid Hormone Receptors 
SP   Side Population 
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STAT5  Signal transducer and activator of transcription 5 
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TGF-α   Transforming Growth Factor-α 
TNF-α   Tumor Necrosis Factor-α 
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WB   Western-blot 
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1.- CANCER 
Cancer is a disease defined by uncontrolled cell expansion, dedifferentiation of the 
abnormally-dividing cells and migration and invasiveness of surrounding and distant 
tissues. The cause for the deregulation of proliferation at the origin of cancer lies in 
accumulative sequential mutations that occur as a result of both genetic instability and 
environmental offences, generating important molecular alterations within the cell that 
interfere with its proliferation.   
 
Cell proliferation is controlled by a balance between proliferative and antiproliferative 
signals to which the cell is submitted. When a cell proliferates it undergoes a repetitive 
cycle of duplication of the genetic information and division, which is known as cell 
cycle. The cell first duplicates its DNA content to generate two identical copies. This 
defines the S phase of the cell cycle (S for synthesis). Then, each copy is segregated to 
one of the two daughter cells resulting from cell division. Segregation and cell division 
define the M phase (M for mitosis). Mitosis is further subdivided in subphases that 
reflect how chromosome segregation occurs. To prepare for synthesis and mitosis, the 
cell undergoes two previous gap phases, called G1 and G2, respectively.   
 
To integrate the stimuli that induce or oppose proliferation, the cell possesses signalling 
pathways that transform both external and internal signals into a cellular response. To 
achieve this, the cell accounts for signal receptors in charge of receiving the signal. This 
is the case, of ErbB receptors, that will be discussed later on. Through a complex 
system of lipid and protein recruitment and interaction, where post-transductional 
modifications such as phosphorylation play a crucial role, the cell activates transcription 
factors that will bind to the promoter of target genes and regulate their transcription, 
giving thus an appropriate response to the stimuli. Misfunctioning of these mechanisms 
may lead to aberrant proliferative responses and, in some cases, to cancer. 
Figure 1. The phases of the cell cycle.  
When cells proliferate they duplicate their DNA 
content and segregate the copies into the daughter 
cells. DNA duplication occurs during the S phase, 
and cell division marks the M phase. These 
processes are separated by gap phases (G1 and G2). 
The period comprising G1, S and G2 phases, in 
which the cell prepares for mitosis, is known as 
interphase. 
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With more than 3 million new cases and 1.7 million deaths each year, cancer represents 
the second most important cause of death in Europe, after cardiovascular disease.  
Depending on the tissue where it originates, cancer can be further classified in 
carcinoma, if it arises from the epithelium, or sarcoma if it originates from mesoderm. 
Leukaemias are neoplasties which start in blood precursors, whereas lymphomas and 
myelomas begin in cells of the immune system. Currently, the most common form of 
diagnosed cancer is breast cancer (13.5% of all cancer cases), followed by colorectal 
cancer (12.9%) and  lung cancer (12.1%). Regarding the number of deaths from cancer, 
breast carcinoma is, after lung cancer and colorectal cancer, the third most common 
cause of death considering both sexes and the leading cause in women (Ferlay et al., 
2007).  
 
 
 
Figure 2. Incidence and mortality of most common cancer types in Spain. 
Data from year 2006. Related to 100,000 inhabitants. 
Source: International Agency for Research on Cancer 
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2.- BREAST CANCER 
The mammary gland originates as an appendage of the skin during foetus development. 
Epithelial cells proliferate within the so-called stroma, surrounding connective tissue 
composed of extracellular matrix, fibroblasts, blood and lymphoid vessels, nerves and 
inmmune cells. As a result, a rudimentary tree-shaped net of ducts is generated. During 
puberty, the exposure of the epithelial cells to oestrogen and progesterone causes 
elongation and side branching of the ducts, at whose end epithelial cells form alveoli, 
giving the mammary gland its final configuration. Alveoli are in charge of producing 
milk upon pregnancy and secrete it into the lumen of the ducts. In the resulting mature 
mammary gland, epithelial cells are organized in two strata: some of the epithelial cells 
are adjacent to the lumen, and are thus named luminal, whereas the so-called basal 
myoepithelial cells form a mesh-like structure between the luminal cells and the 
basement membrane (Hennighausen and Robinson, 2005).  
     
Depending on which structure of the mammary gland is affected by a neoplastic lesion, 
breast cancer is classified on luminal or basal cancer or alternatively in ductal or lobular 
cancer, when ducts or alveoli are affected, respectively. In its early stage, cancer cells 
form a neoplastic mass, which remains embedded in the tissue where it has been 
originated, but separated from the surrounding tissue by the basement membrane. At 
this moment, the carcinoma is called ‘in situ’. However, during cancer progression, the 
basement membrane is progressively degradated and tumour cells invade the stroma. 
Cancer is then classified as ‘invasive’. Most breast tumours arise from the duct 
epithelium, with invasive ductal carcinomas, accounting for over 70% of diagnosed 
breast cancers.  
 
Figure 3. Organization of the 
mature mammary gland. 
Cells are classified in ductal or 
alveolar depending of their 
localization. In addition, cells in 
contact with the lumen are 
considered basal, and cells in 
contact with the basement 
membrane are known as 
myoepithelial. Source: 
(Woodward et al., 2005). 
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In order to efficiently eradicate cancer cells, elucidation of the mechanisms underlying 
tumour progression and identification of new therapeutic agents is of crucial 
importance. Studies from our laboratory and other groups have shown that ligands for 
the Peroxisome Proliferator-Activated Receptor γ (PPARγ) have important 
antitumorigenic effects on breast cancer cells, placing them as important therapeutic 
agents to fight breast cancer. 
 
3.- PPARs 
Peroxisome Proliferator-Activated Receptors (PPARs) are ligand-inducible 
transcription factors that belong to the superfamily of the nuclear hormone receptors, 
which includes receptors for steroid hormones, bile acids, retinoic acids, and thyroid 
hormones (Evans, 1988). These receptors are multi-domain transcription factors that 
bind to specific DNA sequences and induce transcription of target genes. They have a 
N-terminal domain that contains at least one constitutively active transactivation region 
known as ‘activation function-1’ (AF-1) together with sites for phosphorylation and 
docking of regulatory proteins, a highly conserved central domain responsible for DNA 
binding and heterodimerization, a domain which acts as a flexible hinge region and a C-
terminal domain which serves as docking site for cofactors and contains a nuclear 
localization signal and a ligand-dependent transactivation function referred to as AF-2.  
 
PPARs bind to consensus sequences known as PPAR Response Elements (PPRE) in the 
promoter of their target genes. These sequences consist of a directly repeating core site 
separated by one nucleotide (NNN-AGGTCA-N-AGGTCA), and are thus called ‘direct 
repeat 1’ (DR1) (Palmer et al., 1995). PPREs have been identified, among others, in 
genes coding for acylcoenzyme A oxidase, cytochrome P450 4A6, and adipocyte P2. To 
recognize a PPRE, PPARs must form a heterodimer with the retinoid X receptor (RXR), 
which is a common DNA binding partner of the thyroid/steroid receptor family that 
binds 9-cis retinoic acid (Mangelsdorf et al., 1992). Once bound to the PPRE, PPAR 
activates transcription via a mechanism that involves the recruitment of coactivators, 
such as CREB-binding protein (CBP-1), steroid receptor coactivator 1 (SRC-1), and 
receptor interacting protein 140 (RIP140) and corepressors such as nuclear co-
repressors 1-2 (NCoR1-2) and silencing mediator for retinoid and thyroid hormone 
receptors 1-2 (SMRT1-2).  
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There are three PPAR isotypes: PPARα, PPARβ (also called PPARδ, due to parallel 
characterization) and PPARγ (Keller and Wahli, 1993; Sertznig et al., 2007). PPARα 
and PPARβ are deeply implicated in energy homeostasis. PPARα controls transcription 
of genes involved in mitochondrial β-oxidation of free fatty acids, stimulates 
gluconeogenesis, ketone-body synthesis and cholesterol uptake by the liver (Bragt and 
Popeijus, 2008), whereas PPARβ participates in fatty acid oxidation and in 
myelinization and lipid metabolism in the brain (Basu-Modak et al., 1999). Conversely 
to PPARγ, for whom a deep implication in cancer has been established, PPARα and 
PPARβ are mainly in charge of fatty acid metabolism, with few and not fully-elucidated 
implications on tumorigenesis.  
 
3.1.- PPARγ 
The gene encoding for PPARγ (NR1C3) has been identified under six isoforms in 
humans, named PPARγ1-5 and PPARγ7. PPARγ1 and PPARγ2 differ only in 84 
additional nucleotides at the 5’ end of PPARγ2 gene, that encode for 28 additional 
aminoacids. This causes the ligand-independent activation domain of PPARγ2 to be five 
to ten times more effective than that of PPARγ1. The rest of the isoforms are different 
transcripts, but encode for the same protein than PPARγ1. Therefore, there are only two 
resulting proteins: PPARγ1 and PPARγ2, caused by different promoter usage and 
alternative splicing. PPARγ is highly expressed in white and brown adipocytes, immune 
system and at lower levels in skeletal muscle, liver and bone marrow stromal cells, 
fibroblasts and epithelial cells.  
 
PPARγ regulates adipocyte differentiation and lipid storage and release. In fact, one of 
the earliest events in the differentiation of adipocytes is PPARγ expression (Tontonoz et 
al., 1994). Moreover, PPARγ regulates multiple genes implicated in lipid metabolism, 
including lipoprotein lipase (LPL), adipocyte fatty acid binding protein (aP2), acyl-CoA 
synthase, and fatty acid transport protein. In addition, PPARγ regulates insulin 
homeostasis, as activation of PPARγ leads to improvement of insulin sensitivity, and a 
subsequent increase in glucose uptake.  
 
PPARγ has been shown to have antineoplastic effects in several carcinomas (Grommes 
et al., 2004). The ability of PPARγ to inhibit the proliferation of fibroblasts during 
adipose differentiation first suggested that this receptor might be capable of reducing 
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malignant behaviour in neoplastic lesions. This was first examined in human 
liposarcoma, a malignancy of the adipose lineage. Most liposarcomas have been found 
to express higher levels of PPARγ than other sarcomas, and cells grown from 
liposarcomas were found to have a dramatic differentiation response to PPARγ ligands 
(Tontonoz et al., 1997). Based on these findings, later studies reported that PPARγ 
activation inhibits proliferation and induces apoptosis of malignant cells from different 
lineages such as gastric carcinoma (Sato et al., 2000), colorectal carcinoma (Kubota et 
al., 1998), pancreatic carcinoma (Elnemr et al., 2000), hepatocellular carcinoma and 
non-small-cell lung cancer (Keshamouni et al., 2004). More recently, its antineoplastic 
capacities have been proved in glioma (Grommes et al., 2006). In addition, PPARγ 
ligands have been reported to inhibit angiogenesis and neovascularisation both in vitro 
and in vivo (Panigrahy et al., 2002). Altogether, these observations suggest that 
induction of differentiation and apoptosis by activation of PPARγ may represent a 
promising novel therapeutic approach for cancer as already demonstrated for 
liposarcoma. In accordance with this, we and others have obtained evidence that 
activation of PPARγ by different ligands results in a more differentiated, less malignant 
state, a reduction in growth rate and an enhancement of apoptosis of several breast 
cancer cell lines. Specifically we have shown that the PPARγ ligand 15-deoxi-Δ12-14-
Prostaglandin J2 almost completely blocks phosphorylation and subsequent activation of 
the ErbB receptor tyrosine kinase family and, therefore, plays a suppressive regulatory 
role in the tumour growth of human breast carcinoma cells that express these receptors 
(Pignatelli et al., 2001). 
 
3.2.- PPARγ ligands 
PPARγ can be activated upon binding of a wide variety of hydrophobic ligands. 
Unsaturated fatty acids are commonly found among the natural activators of PPARγ. 
These are dietary components that, in general terms, are good activators of all PPAR 
subtypes, especially the 18-20 carbon unsaturated fatty acids. However, the highest 
activation rate of PPARγ is achieved by the endogenous eicosanoid 15-deoxi-Δ12-14-
prostaglandin J2 (15d-PGJ2), with proven antiproliferative effects on several carcinoma 
types. There are also synthetic molecules capable of significantly activating PPARγ. 
This group of synthetic activators includes the group of insulin sensitizers known as 
thiazolidinediones (TZDs) and the non-steroideal anti-inflammatory drugs (NSAIDs). 
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3.2.1.- Thiazolidinediones 
Thiazolidinediones (TZDs) are insulin sensitizers that improve glucose uptake and 
lower hyperglycaemia and hyperinsulinaemia. Thus, they have been used in the 
treatment for type II diabetes mellitus, although some reports suggest that they could 
increase the risk of heart failure (Home et al., 2009).  
 
This group of synthetic PPARγ ligands, which includes among others rosiglitazone, 
pioglitazone, ciglitazone and troglitazone, has also been reported to inhibit the growth 
and promote apoptosis in different types of carcinomas. Activation of PPARγ by 
rosiglitazone, for example, induces inhibition of cell growth and/or induction of 
apoptosis in prostate cancer, hepatocellular carcinoma and breast carcinoma (Grommes 
et al., 2004). Similar effects have been observed upon treatment with pioglitazone in 
gastric cancer and breast carcinoma (Sohda et al., 1990). Troglitazone, another member 
of the family of the TZDs, exhibits antineoplastic effects in a wide variety of tumours, 
both in vitro and in vivo. Considering breast cancer, troglitazone has been reported to 
inhibit proliferation of breast carcinoma cells (Elstner et al., 1998) and cause regression 
or stasis of breast tumours in rats (Pighetti et al., 2001). Conversely, a phase II study 
conducted on patients with advanced refractory breast cancer was not able to report 
benefit from treatment with troglitazone (Burstein et al., 2003). However this study had 
to be concluded in advance due to withdrawal of troglitazone from clinical use as 
significant adverse events of severe liver toxicity were reported.  
 
3.2.2.- Thiadiazolidinones (TDZDs) 
The compounds of the family of the thiadiazolidinones (TDZDs) show structure 
similarity with the TZDs group of PPARγ ligands that includes rosiglitazone and 
pioglitazone, among others. Although these compounds were originally developed as 
non-ATP competitive inhibitors of GSK-3β (Martinez et al., 2002), data from our group 
indicate that they are efficient activators of PPARγ receptors. Moreover, our data reflect 
that inhibitors of PPARγ impair the effects exerted by TDZDs, strongly suggesting that 
their action is mediated by this receptor (Luna-Medina et al., 2005). In addition, TDZDs 
have been shown to have potent anti-inflammatory effects, including downregulation of 
cycloxygenase type 2 (COX-2), a property shared with the natural PPARγ ligand 15d-
PGJ2.  
16 
 
 
Although TDZDs have been reported by us as well as other authors to promote 
cytoprotective effects in several tissues (Luna-Medina et al., 2007), it has been recently 
shown that one of these compounds, known as TDZD-8, causes death of leukaemia 
stem cells (Guzman et al., 2007), suggesting a possible role in cancer therapy. 
 
3.2.3.- Non-Steroideal Anti-Inflammatory Drugs (NSAIDs) 
Non-Steroideal Anti-Inflammatory Drugs (NSAIDs) such as indometacin and ibuprofen 
are cyclooxygenase inhibitors that also bind and activate PPARγ in vitro at high 
concentrations, causing terminal adipocyte differentiation (Lehmann et al., 1997). Some 
of them are also activators of  PPARα, inducing peroxisomal activity in hepatocytes. 
 
3.2.4.- 15-deoxi-Δ12-14-Prostaglandin J2  
Prostaglandins are derivatives of arachidonic acid liberated from membrane 
phospholipids by phospholipase A2 (Straus and Glass, 2001). Upon release, arachidonic 
acid is converted by the enzyme cyclooxygenase (COX, also known as PGH synthase) 
to PGH2, an unstable intermediate that will be enzimatically processed. Depending on 
the enzyme that catalyses the reaction, PGH2 will originate one of the different 
biologically active prostanoids: PGD2, PGE2, PGF2α, PGI2, or thromboxane A2. Each of 
them will be the precursor of a series of derivatives with biological effects. Thus, PGD2 
spontaneously undergoes chemical dehydratation to form PGJ2. Prostaglandins from the 
J series contain an electrophilic carbonyl moiety in their cyclopentenone ring that is 
responsible for their reactivity with other molecules. PGJ2 can undergo further 
dehydratation by loss of the 15-hydroxyl group, which, coupled with migration of the 
13,14-double bond, results in the formation of 15-deoxi-Δ12-14-PGJ2 (15d-PGJ2), that 
contains a second potentially reactive electrophilic carbon on one of its side chains.  
Figure 4. Structure of the thiadiazolidinones compounds NP00111 and NP01138 and the 
thiazolidinedione rosiglitazone. 
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15d-PGJ2 plays an important role in adipogenesis, as it is an inducer of adipocyte 
differentiation (Forman et al., 1995; Kliewer et al., 1995). In addition, 15d-PGJ2 is a 
potent anti-inflammatory agent capable of repressing the expression of inducible nitric 
oxide synthase (iNOS), tumour necrosis factor-α (TNFα) and COX-2 in activated 
monocytes (Ricote et al., 1998) and inhibiting the production of inflammatory cytokines 
(Jiang et al., 1998). Moreover, 15d-PGJ2 enhances platelet production (O'Brien et al., 
2009) and protects against oxidative stress. 
 
Figure 5. Schematic representation of the synthesis pathway of 15d-Δ12-14PGJ2. 
Source: (Kim and Surh, 2006) 
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15d-PGJ2 has also been shown to have important antineoplastic effects in vitro and in 
vivo on prostate carcinoma, gastric cancer, colon carcinoma, glioma, breast carcinoma 
and pancreatic cancer (Grommes et al., 2004). These effects comprise inhibition of 
growth, promotion of apoptosis, and arrest of the cell cycle, an effect attributed to 
downregulation of cyclin D1. In the later years, 15d-PGJ2 has emerged as an inhibitor of 
angiogenesis (Fu et al., 2006) and its induction of apoptosis has been related to 
activation of p53 (Ho et al., 2008). In agreement with all this data, we have recently 
shown that 15d-PGJ2 inhibits breast cancer cell proliferation, induces apoptosis and 
causes mitochondrial dysfunction, suggesting that the anti-neoplastic effects of 15d-
PGJ2 can be triggered by multiple mechanisms (Pignatelli et al., 2005).  
 
Some of the anticancer effects exerted by 15d-PGJ2 are based on its ability to activate 
PPARγ. However, other effects are not mediated by PPARγ, but are due to the capacity 
of 15d-PGJ2 to directly interact with other proteins. The presence of two highly reactive 
electrophilic centres in 15d-PGJ2 allows the formation of covalent adducts via a Michael 
addition reaction with nucleophiles such as cysteine thiol groups present in proteins 
(Kim and Surh, 2006). This is the mechanism by which 15d-PGJ2 binds several 
transcription factors, such as nuclear factor-kB (NF-kB) (Straus et al., 2000) and the β-
subunit of the IKB kinase (IKK) complex (Rossi et al., 2000) and regulates their 
transcriptional activity. In a similar way, 15d-PGJ2 interacts with cell signal transducers, 
thus interfering in central signalling pathways. This is the case, among others, of H-Ras, 
to whom 15d-PGJ2 directly binds, inducing its activation (Oliva et al., 2003). 
 
4.- Erythroblastic leukemia viral oncogene homologues (ErbBs) 
The ErbB family of proteins are transmembrane receptors with intrinsic tyrosine kinase 
activity in their intracellular domain that allows them to transfer phosphate groups to 
tyrosine residues contained in cellular substrates. This family, that takes its name from 
the homology of one of its members to the erythroblastoma viral gene product, v-erbB, 
comprises four receptors (ErbB1-4, also known as HER1-4) with several extracellular 
ligands, all of them containing a conserved epidermal growth factor (EGF) domain 
(Hynes and Lane, 2005). These ligands are classified in three groups: 
· EGF, transforming growth factor-α and amphiregulin, which bind to ErbB1. 
· Betacellulin, heparin-binding EGF and epiregulin, which bind both EGFR and ErbB4. 
· Neuregulins (NRG), bind only ErbB4 (NRG3, NRG4) or also ErbB3 (NRG1, NRG2). 
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ErbBs exist as inactive transmembrane monomers in tissues of neural, epithelial and 
mesenchymal origin. Ligand binding to their extracellular domain initiates a 
conformational rearrangement in the receptor leading to its homo or heterodimerization. 
Then, each member of the dimer uses its intracellular protein tyrosine kinase domain to 
phosphorylate its partner on its cytosolic domain, inducing thus its activation (Citri and 
Yarden, 2006). Interestingly, ErbB2  and Erb3 are non-autonomous: no ligand has been 
identified for ErbB2, and ErbB3 is defective in kinase activity. Despite this lack of 
autonomy, both ErbB2 and ErbB3 form heterodimeric complexes with other ErbBs that 
are capable of generating potent cellular signals. Moreover, they can heterodimerize 
with each other to form an ErbB2/ErbB3 complex that gives rise to one of the most 
potent oncogenic signals described (Holbro et al., 2003a). 
 
ErbB1, ErbB2 and ErbB3 are all implicated in the development and progression of 
cancer. Patients with cancer whose tumours have alterations in ErbB receptors tend to 
have a more aggressive disease, and predicts a poor clinical outcome. The role of ErbB4 
in oncogenesis is less clear. Current data indicate that this receptor might be involved in 
inhibition of cell growth rather than proliferation. 
 
.- ErbB1 
ErbB1 binds to multiple ligands, although his ability to bind the epidermal growth 
factor has caused that this receptor is commonly named epidermal growth factor 
receptor (EGFR). Upon binding, ErbB1 can form homodimers as well as three 
functional heterodimers. Knock-out studies of genes coding for specific ligands of 
ErbB1 demonstrated a marked functional redundancy between the ligands: knock-out 
mice of EGF show no significant phenotype, and alterations in transforming growth 
factor-α (TGF-α) knock-out mice are restricted to eye abnormalities. 
 
Gene amplification leading to ErbB1 overexpression is often found in human cancers, 
together with mutations and deletions that result in constitutive kinase activity (Holbro 
et al., 2003b). Furthermore, in many tumours EGF-related growth factors are produced 
by the tumour cells themselves or by surrounding stromal cells, leading to constitutive 
ErbB1 activation. Aberrantly increased ErbB1 signalling has been reported in 
glioblastomas, lung carcinomas, prostate cancer and breast carcinoma.. 
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.- ErbB2 
ErbB2 (also referred as neu and HER2) is the preferred heterodimeric partner of the 
other three ErbB family members. Although no direct ligand has been identified for this 
receptor to date, it exits in a conformational state that is constitutively active for 
dimerization. ErbB2-containing heterodimers have a higher affinity and broader 
specificity than other heterodimeric receptor complexes, and the ErbB2/ErbB3 
heterodimer is considered the most potent ErbB complex with respect to strength of 
interaction, ligand-induced tyrosine phosphorylation and downstream signalling 
(Baselga and Swain, 2009). 
 
ERBB2 amplification and overexpression have been observed in several types of human 
tumours such as ovarian cancer, gastric carcinoma, salivary gland tumours and in 20-
30% of human breast cancers (Slamon et al., 1989). Moreover, this expression profile is 
associated with a poor prognosis. Overexpression promotes spontaneous ErbB2 
dimerization in the absence of a ligand and constitutive receptor activation, leading to 
aberrantly increased levels of ErbB2-mediated signalling, which promotes 
tumorigenesis. According to this, results from our group show that proliferation and 
survival of human breast cancer cells is due to activation of phosphatidylinositol 3-
kinase (PI3K) and mitogen-activated protein kinase (MAPK) signalling cascades 
respectively, as a result of signalling through the ErbB2/ErbB3 heterodimer (Pignatelli 
et al., 2001). 
 
.- ErbB3 
ErbB3 can bind to four different ligands but lacks intrinsic tyrosine kinase activity, as it 
is unable to bind adenosine triphosphate (ATP). This is the reason why ErbB3 cannot 
homodimerize. Nonetheless, the cytoplasmic domain of ErbB3 undergoes tyrosine 
phosphorylation upon heterodimerization, and this allows the recruitment and activation 
of PI3K, which promotes tumour proliferation. ErbB3 is the preferred dimerization 
partner when signalling occurs through the PI3K pathway, probably because although 
ErbB1 and ErbB2 can interact with and activate PI3K through adaptor proteins, binding 
via ErbB3 is direct and the resulting activation is of PI3K pathway is more intense 
(Hellyer et al., 1998). 
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Alterations in ErbB3 signalling have been reported in breast carcinoma, ovarian cancer, 
lung and prostate carcinoma, among others. In all these cases, but especially in breast 
cancer, ErbB3 is commonly expressed along with ErbB2 (Lee-Hoeflich et al., 2008). 
Interestingly, amplification of ErbB3 alone has also been observed in lung cancer, and 
growing data indicate that ErbB3 expression is upregulated in breast cancer in order to 
compensate for the inhibition of other members of the ErbB family (Sergina et al., 
2007). 
 
.- ErbB4 
ErbB4 shows a high similarity to ErbB1 in ligand specificity and recruitment of adaptor 
proteins. Interestingly, although ErbB4 acts mainly as a receptor tyrosine kinase in 
plasma-membrane signalling processes, it also undergoes catalytic cleavage generating 
a chaperone that facilitates the translocation into the nucleus of several transcription 
factors such as signal transducer and activator of transcription 5 (STAT5) (Williams et 
al., 2004). More recent studies on the still poorly unknown functions of ErbB4 indicate 
that suppression of its function leads to inhibition of cell growth in breast cancer 
(Hollmen et al., 2009). 
 
5.- PROTEIN PHOSPHOTYROSINE PHOSPHATASES 
Phosphotyrosine phosphatases (PTPs) are proteins in charge of dephosphorylating 
tyrosine residues. Since protein tyrosine phosphorylation is a key event in the activation 
of signalling cascades, PTPs constitute a key regulatory mechanism in signal 
modulation (Tonks, 2006). In the case of ErbB-mediated signalling, several 
phosphatases have been implicated in the regulation of the pathway, a property that is 
based on the presence within the phosphatase of domains capable of recognizing and 
binding phosphorylated tyrosines. This is the case of Src-homology-2 (SH2) and 
phosphotyrosine binding (PTB) domains. Thus, for example, EGFR is bound and 
dephosphorylated by PTP1B phosphatase, RPTPσ, density-enhanced phosphatase 1 
(DEP1) and SH2-domain containing phosphatase-1 (SHP-1) (Ostman and Bohmer, 
2001), whereas ErbB2 has been shown to be dephosphorylated by the PEST-motif 
containing brain-derived phosphatase 1 (BDP1) (Gensler et al., 2004) and positively 
regulated by the SH2-domain containing phosphatase-2 (SHP-2) (Zhou and Agazie, 
2009). 
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.- SHPs 
SHPs are a family of cytosolic tyrosine phosphatases which contain SH2 domains. This 
family comprises SHP-1, SHP-2, corkscrew (Csw) from Drosophila and PTP-2 from 
Caenorhabditis elegans. SHP-1 and SHP-2 have highly homologous primary structures 
(55% identity). Both consist of two SH2 domains and a tyrosine phosphatase domain 
followed by a highly basic C-terminal tail that contains phosphorylation sites (Tyr536 
and Tyr564 for SHP-1) and regulates substrate recognition and activity (Pei et al., 1994; 
Zhang et al., 2003). Interestingly, this regulatory C-terminal tail is the region where 
SHP-1 and SHP-2 show lower sequence homology (about 15% identity), a fact that 
could explain their divergences in distribution, functions and targets. Regardless of their 
structure similarity, SHP-1 and SHP-2 differ greatly in cellular distribution and 
biological function. SHP-1 is predominantly expressed in haematopoietic and epithelial 
cells, and behaves as a negative regulator of several receptor tyrosine kinases. In 
contrast, SHP-2 is expressed ubiquitously in cells with various origins and acts 
primarily as a positive regulator (Plutzky et al., 1992), with functions antagonizing 
those of SHP-1 in several systems (Qu et al., 2001). 
 
SHP1 
SHP-1, also known as PTP1C, SH-PTP1, HCP and PTPN6, is present under different 
isoforms in haematopoietic and epithelial cells (Poole and Jones, 2005), where it acts as 
a negative regulator of cell signalling. SHP-1 has been proposed to antagonize growth-
promoting signals initiated by receptor tyrosine kinases, since mice lacking SHP-1 
protein show hyperproliferation of myeloid and lymphoid progenitors and enhanced 
response to growth factors (Tapley et al., 1997). In addition, SHP-1 messenger RNA 
(mRNA) and protein levels are decreased in most lymphomas and leukaemias (Oka et 
al., 2001) and forced expression of SHP-1 in lymphoma and leukaemia cell lines results 
in decreased proliferation (Bruecher-Encke et al., 2001). Similar results have been 
obtained in other cancer types, including breast cancer, where transfection of SHP-1 
inhibits the growth of the SHP-1-deficient HTB26 cell line (Wu et al., 2003), thereby 
confirming the implication of this phosphatase in opposing cell growth.  
 
In breast cancer cells, SHP-1 dephosphorylates several receptor tyrosine kinases such as 
EGFR (Tomic et al., 1995), platelet-deriver growth factor receptor (PDGF) (Yu et al., 
1998) and ErbB2 (Vogel et al., 1993), suggesting that the antiproliferative effect of the 
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phosphatase is related to silencing of the signalling pathways initiated by these 
receptors. In fact, overexpression of SHP-1 leads to a decrease in the phosphorylation 
level of EGFR and viceversa (Keilhack et al., 1998). 
 
One peculiarity of SHP-1 is that phosphorylation on its C-terminal region determines its 
activation. Phosphorylation on Tyr536 by the insulin receptor tyrosine kinase has been 
reported to induce its activation (Uchida et al., 1994). Similarly, SHP-1 experiences an 
increase in its catalytic activity upon phosphorylation on tyrosine by Src (Frank et al., 
2004) and in human platelets upon phosphorylation on both tyrosine and serine residues 
(Li et al., 1995). The C-terminal tail of SHP-1 also accounts for a nuclear localization 
signal, which is blocked in the native protein but becomes active upon stimulation with 
EGF and causes traslocation of SHP-1 from the cytosol to the nucleus in monkey 
embryonic kidney COS7 cells. Conversely, SHP-1 presents a cytosolic distribution in 
H9 hematopoietic cells (He et al., 2005) and in several cancer cell lines studied (human 
epithelial carcinoma A431 and human colonic adenocarcinoma HT29 cells), 
independently of EGF stimulation. 
 
SHP-2 
Regardless of its sequence similarity, SHP-2 (PTP1D, PTP2C, SH-PTP2, Syp or 
PTPN11) exerts functions antagonizing those of SHP-1. SHP-2 directly binds several 
receptor tyrosine kinases such as EGFR and ErbB2 and acts as a positive regulator of 
their signalling, thus promoting cell growth and survival. In fact, its activation is a 
requirement in certain systems to achieve activation of PI3K or MAPK pathways (Wu 
et al., 2001). Moreover, SHP-2 has been reported to promote cell transformation 
(Agazie et al., 2003) through positively regulating ErbB2 signalling (Zhou and Agazie, 
2009). 
 
.- BDP1 
BDP1 is a phosphatase enriched in PEST sequences, which are characterized by their 
high content in proline (P), glutamic acid (E), serine (S) and threonine (T). BDP1 has 
been reported to negatively regulate ErbB2 activation in breast cancer cell lines, leading 
to reduced activation of MAPKs (Gensler et al., 2004). 
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6.- CANCER STEM CELLS 
Traditionally, cancer was believed to follow a clonal evolution model by which 
stochastic mutations accumulate in a cell or in a group of cells over-time, providing 
these cells with a growth advantage over the adjacent tissue that favours their expansion 
as competition during natural selection occurs. Thus, any cell would have the potential 
to originate a tumour. However, there is increasing evidence that supports that cancer 
follows a stem cell model, that posits that tumorigenesis is driven by a subset of cells 
with unlimited proliferative potential resulting from their capacity to undergo 
asymmetric divisions that produce an exact copy of the cell (self-renewal) and a 
daughter cell that differentiates. Thereby, cells within a tumour would be functionally 
heterogeneous, as only few cells would be responsible for the progression of the tumour 
by generating the diverse cells that comprise it. Although both models are not mutually 
exclusive, transplantation studies of single cells into immunodeficient mice indicate that 
only cells which expressed a determined combination of surface markers were able to 
regenerate the whole tumour (Bhatia et al., 1997). These cancer stem cells have been 
described in several malignancies after serial transplantation studies, and the membrane 
antigens that characterize them vary depending on the tissue of origin. Therefore, they 
have been described as CD44+/CD24-/low in breast cancer (Al-Hajj et al., 2003) and 
CD133+ in colon carcinoma (O'Brien et al., 2007), lung carcinoma and glioma (Singh et 
al., 2004). 
 
Together with xenografts, cultures in non-adherent conditions have contributed to the 
prospective identification of cancer stem cells. When grown as suspension cultures, 
only cells with stem properties survive and proliferate, originating spheres which 
represent the progeny of a single stem cell and are enriched in progenitor cells (Ponti et 
al., 2005). This property of being capable to grow under non-adherent conditions is 
shared with normal tissue stem cells (Dontu et al., 2003). Interestingly, several studies 
report that spheres are preferentially generated in vitro by cells comprised in the side 
population, a minor subpopulation of cells detected by flow cytometry thanks to their 
capacity to differentially efflux the fluorescent DNA-binding dye Hoechst 33342 due to 
their overexpression of the multidrug resistance transporter ATP-binding cassette G2 
(ABCG2) (Goodell et al., 1996). 
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However, great controversy surrounds both the techniques employed to define the 
markers and their accurateness. Big divergences have been observed in orthotopic 
xenograft models depending on the mouse strain used (Quintana et al., 2008) and on the 
experimental conditions, such as use of humanized microenvironments or artificial 
matrices e.g. Matrigel. Similarly, the CD44+/CD24-/low phenotype defined for breast 
cancer stem cells does not correlate with poor prognosis, a fact that has lead other 
groups to propose alternative markers such as aldehyde dehydrogenase-1 (ALDH1) 
(Ginestier et al., 2007). 
 
Prospective identification and isolation of cancer stem cells is a main challenge in the 
actual scientific scope, since to be efficient, therapies must eradicate this subset of cells 
responsible of the driving and progression of tumorigenesis. In case any of these cells 
persists after treatment the tumour will relapse. Thus, assessment of the antitumorigenic 
properties of a drug in the cancer stem population is of crucial relevance to determine its 
potential as therapeutic agent. 
 
 
In this work, we have further analyzed the mechanism of action of PPARγ ligands in 
breast cancer cells and their effect on the cancer stem cell population. 
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1.- CÁNCER 
El cáncer es una enfermedad caracterizada por expansión celular descontrolada, 
desdiferenciación de las células con división anómala y migración e invasividad de los 
tejidos circundantes y distantes. La causa de esta desregulación de la proliferación que 
da origen al cáncer radica en la acumulación de sucesivas mutaciones que aparecen 
como resultado de inestabilidad genética y daños causados por el ambiente y generan 
importantes alteraciones moleculares en la célula que interfieren con su proliferación. 
 
La proliferación celular está controlada por un equilibrio entre señales proliferativas y 
antiproliferativas. Cuando una célula prolifera entra en un ciclo continuo de duplicación 
de la información genética y división que se conoce como ciclo celular. La célula 
primero duplica su contenido en ADN para generar dos copias idénticas. Este hecho 
define la fase S del ciclo célular (S de síntesis). Entonces, cada copia es segregada a 
sendas células hijas resultantes de la división celular. La segregación y la división 
celular definen la fase M (de mitosis). La  mitosis se divide a su vez en subfases que 
reflejan cómo ocurre la segregación. Para prepararse para la síntesis y la mitosis, la 
célula pasa por sendas fases previas de preparación, denominadas G1 y G2.   
 
Para integrar los estímulos que inducen o se oponen a la proliferación la célula cuenta 
con vías de señalización que transforman las señales externas e internas en una 
respuesta celular. Para ello, la célula posee receptores de señales encargados de captar la 
señal, como es el caso de los receptores ErbB, a los que nos referiremos más adelante. 
Mediante un complejo sistema de reclutamiento e interacción de lípidos y proteínas 
donde las modificaciones post-transduccionales juegan un papel primordial, la célula 
activa factores de transcripción que se unirán al promotor de determinados genes diana 
y regularán su transcripción, dando de esta manera una respuesta apropiada al estímulo. 
Figura 1. Las fases del ciclo celular.  
Cuando las células proliferan duplican su 
contenido en ADN y segregan las copias en las 
células hijas. La duplicación del ADN ocurre 
durante la fase S, y la división celular marca la 
fase M. Estos procesos están separados por fases 
espaciadoras (G1 y G2 respectivamente). El 
periodo que comprende las fases G1, S y G2, 
durante el que la célula se prepara para la 
mitosis, se denomina interfase. 
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El mal funcionamiento de estos mecanismos puede acarrear respuestas proliferativas 
erróneas y, en algunos casos, cáncer. 
 
Con más de 3 millones de nuevos casos y 1,7 millones de muertes cada año, el cáncer 
representa la segunda causa de muerte en Europa, después de las enfermedades 
cardiovasculares. Dependiendo de su origen el cáncer puede ser clasificado en 
carcinoma, si deriva de epitelio, o sarcoma, si se origina del mesodermo. Las leucemias 
se inician en precursores sanguíneos y los linfomas y los mielomas comienzan en 
células del sistema inmune. Actualmente, el tipo de cáncer más comúnmente 
diagnosticado es el cáncer de mama (con el 13,5% de todos los casos de cáncer), 
seguido de cáncer colorrectal (12,9%) y de pulmón (12,1%). Teniendo en cuenta el 
número de muertes debidas a cáncer, el carcinoma mamario es, después del cáncer de 
pulmón y el colorrectal, la tercera causa más común de muerte si consideramos ambos 
sexos y la primera en el caso de mujeres (Ferlay et al., 2007).  
 
 
Figura 2. Incidencia y mortalidad del cáncer en España. 
Datos del año 2006. Referidos a 100.000 habitantes. 
Fuente: International Agency for Research on Cancer 
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2.- CÁNCER DE MAMA 
La glándula mamaria se origina como un apéndice de la piel durante el desarrollo fetal. 
Las células epiteliales proliferan dentro del estroma, tejido conectivo circundante 
compuesto por matriz extracelular, fibroblastos, vasos sanguíneos y linfáticos, nervios y 
células del sistema inmune. Como resultado, se genera una primitiva red de ductos en 
forma de árbol. Durante la pubertad, la exposición de las células epiteliales a estrógeno 
y progesterona causa la elongación y la ramificación de los ductos, en cuya parte final 
las células epiteliales forman los alveolos, que producirán leche durante el embarazo, 
secretándola a la luz de los ductos. En la glándula mamaria adulta resultante las células 
epiteliales se organizan en dos estratos: algunas de las células epiteliales quedan 
adyacentes a la luz, y son llamadas por ello luminales, mientras que otras, llamadas 
células mioepiteliales, forman una estructura en forma de malla entre las células 
luminales y la membrana basal (Hennighausen and Robinson, 2005).  
 
Dependiendo de qué estructura de la glándula mamaria esté afectada por una lesión 
neoplásica, el cáncer de mama se clasifica en cáncer luminal o basal, o, 
alternativamente, en ductal o lobular cuando los ductos o los alveolos están afectados, 
respectivamente. En su etapa temprana, las células cancerosas forman una masa 
neoplásica que permanece incluida en el tejido donde se originó, pero separada del 
tejido circundante por la membrana basal. En este estado, el carcinoma es denominado 
“in situ”. Durante la progresión del cáncer, la membrana basal es degradada 
progresivamente, y las células cancerosas invaden el estroma. El cáncer es clasificado 
entonces como “invasivo”. La mayoría de los tumores de mama derivan de ductos del 
epitelio, siendo los carcinomas ductales invasivos los más frecuentes, al constituir más 
del 70% de los tumores diagnosticados. 
Figura 3. Organización de la 
glándula mamaria adulta. 
Las células se clasifican en 
ductales o alveolares según su 
localización. Además, las 
células en contacto con la luz 
son denominadas basales y las 
que están en contacto con la 
membrana basal mioepiteliales. 
Fuente: (Woodward et al., 2005) 
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Con el fin de erradicar de modo eficaz las células cancerígenas, desenmascarar los 
mecanismos que determinan la progresión tumoral así como identificar nuevos agentes 
terapéuticos y su mecanismo de acción es de vital importancia. Estudios de nuestro 
laboratorio junto con los de otros grupos muestran que los ligandos del Receptor 
Activado por Proliferadores Peroxisomales γ (PPARγ) poseen importantes efectos 
antitumorigénicos en células de cáncer de mama, lo que los sitúa como importantes 
agentes terapéuticos en la lucha contra el cáncer de mama. 
 
3.- PPARs 
Los Receptores Activados por Proliferadores Peroxisomales (PPARs) son factores de 
transcripción inducibles por ligando que pertenecen a la superfamilia de los receptores 
de hormonas nucleares, que agrupa a los receptores de esteroides, ácidos biliares, ácido 
retinoico y hormonas tiroideas (Evans, 1988). Estos receptores son factores de 
transcripción multi-dominio que se unen a secuencias específicas del DNA llamadas 
elementos de respuesta e inducen así la transcripción de sus genes diana. Cuentan con 
un dominio N-terminal que contiene al menos una región de transactivación 
constitutivamente activa denominada “función de activación-1” (AF-1) junto a sitios 
para la fosforilación y el anclaje de proteínas reguladoras, un dominio central altamente 
conservado responsable de llevar a cabo la unión al ADN y la heterodimerización, un 
dominio flexible que actúa de bisagra y un dominio C-terminal que sirve como lugar de 
anclaje de cofactores y contiene una secuencia de localización nuclear y una función de 
transactivación dependiente de ligando llamada AF-2. 
 
Los PPARs se unen a secuencias consenso en el promotor de sus genes diana 
denominadas Elementos de Respuesta a PPAR (PPRE). Estas secuencias consisten en 
repeticiones directas separadas por un nucleótido (NNN-AGGTCA-N-AGGTCA), por 
lo que son llamadas “repeticiones directas-1” (DR1) (Palmer et al., 1995). Se han 
identificado PPREs entre otros en genes que codifican para la acilcoenzima A oxidasa, 
el citocromo P450 4A6 y aP2. Para reconocer un PPRE, los PPARs deben formar 
previamente un heterodímero con el receptor X retinoide (RXR), el cual es un miembro 
de la familia de los receptores tiroideos/esteroideos que une ácido 9-cis retinoico y es 
frecuentemente copartícipe de la unión a ADN de otros factores de transcripción 
(Mangelsdorf et al., 1992). Una vez unido al PPRE, PPAR activa la transcripción 
mediante un mecanismo que involucra el reclutamiento de complejos coactivadores, 
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como la proteína de unión a CREB (CBP-1), el coactivador 1 del receptor de esteroides 
(SRC-1), la proteína 140 de interacción con receptores (RIP140) y correpresores como 
los correpresores nucleares 1-2 (NCoR1-2) y el mediador silenciador de los receptores 
1-2 de hormonas retinoides y tiroideas (SMRT1-2).  
 
Existen tres isotipos de PPAR: PPARα, PPARβ (también llamado PPARδ, debido a 
caracterización paralela) y PPARγ (Keller and Wahli, 1993; Sertznig et al., 2007). 
PPARα y PPARβ están profundamente implicados en la homeostasis energética. 
PPARα controla la transcripción de genes que participan en la β-oxidación mitocondrial 
de ácidos grasos libres presentes en el plasma, estimula la gluconeogénesis, la síntesis 
de cuerpos cetónicos y la captación de colesterol por el hígado (Bragt and Popeijus, 
2008), mientras que PPARβ participa en la oxidación de ácidos grasos y en la 
mielinización y el metabolismo lipídico en el cerebro (Basu-Modak et al., 1999). 
Contrariamente a lo que sucede con PPARγ, para quien se ha establecido una profunda 
implicación en cáncer, PPARα y PPARβ intervienen principalmente en el metabolismo 
de ácidos grasos, con pocas y no claramente descritas implicaciones en tumorigénesis.  
 
3.1.- PPARγ 
El gen que codifica para PPARγ (NR1C3) ha sido identificado bajo seis isoformas en 
humanos, llamadas PPARγ1-5 y PPARγ7. PPARγ1 y PPARγ2 se diferencian sólo por la 
existencia de 84 nucleótidos adicionales en el extremo 5’ del gen PPARγ2, los cuales 
codifican para 28 aminoácidos adicionales. Esto hace que el dominio de activación 
independiente de ligando de PPARγ2 sea de cinco a diez veces más eficiente que el de 
PPARγ1. El resto de isoformas son distintos transcritos, pero codifican la misma 
proteína que PPARγ1, de modo que sólo hay dos proteínas resultantes: PPARγ1 y 
PPARγ2, causadas por distinto uso de promotor y procesado alternativo de los exones. 
PPARγ se expresa de manera abundante en tejido adiposo blanco y marrón y en células 
del sistema inmune. También se encuentra, aunque en menor medida, en músculo 
esquelético, hígado y células del estroma de la médula ósea, fibroblastos y células 
epiteliales. 
 
PPARγ regula la diferenciación de adipocitos y el almacenamiento y la liberación de 
lípidos. De hecho, su expresión es uno de los eventos iniciales en la diferenciación de 
los adipocitos (Tontonoz et al., 1994). Además, PPARγ regula la expresión de multitud 
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de genes implicados en el metabolismo lipídico, incluyendo la lipoproteína lipasa 
(LPL), la proteína de unión a ácidos grasos (aP2), la acil-CoA sintasa, y la proteína 
transportadora de ácidos grasos. A ello se suma que PPARγ regula la homeostasis de 
glucosa, ya que mejora la sensibilidad a insulina, aumentando así la captación de 
glucosa. 
 
Se ha demostrado que PPARγ tiene efectos antineoplásicos en varios tipos de carcinoma 
(Grommes et al., 2004). La capacidad de PPARγ de inhibir la proliferación de 
fibroblastos durante la diferenciación adipocítica sugirió que este receptor podía ser 
capaz de reducir la transformación celular, capacidad que fue evaluada inicialmente en 
liposarcoma humano. Se ha observado que la mayoría de los liposarcomas expresan 
cantidades más elevadas de PPARγ que otros sarcomas, y que células crecidas de 
liposarcomas diferencian en respuesta a ligandos de PPARγ (Tontonoz et al., 1997).  
Basándose en estas observaciones, estudios posteriores describieron que la activación de 
PPARγ inhibe la proliferación e induce la apoptosis de células tumorales de distintos 
linajes, como es el caso del carcinoma gástrico (Sato et al., 2000), colorrectal (Kubota et 
al., 1998), pancreático (Elnemr et al., 2000), hepatocelular y del cáncer de pulmón no 
microcítico (Keshamouni et al., 2004). Recientemente esta capacidad antineoplásica ha 
sido demostrada también en glioma (Grommes et al., 2006). Además, se ha descrito que 
PPARγ inhibe la angiogénesis y la neovascularizacion tanto in vitro como in vivo 
(Panigrahy et al., 2002). Todo ello sugiere que la inducción de diferenciación y 
apoptosis por la activación de PPARγ puede constituir un prometedor abordaje 
terapéutico del cáncer, tal y como ha sido demostrado en el caso del liposarcoma. De 
acuerdo con esto, nuestro grupo, así como otros laboratorios, ha obtenido evidencias de 
que la activación de PPARγ por diferentes ligandos conduce a un estado más 
diferenciado y menos transformado, una reducción en la tasa de crecimiento y un 
aumento de la apoptosis de varias líneas celulares de cáncer de mama. Concretamente, 
nuestros datos demuestran que el ligando natural de PPARγ 15-deoxi-Δ12-14-
Prostaglandina J2 bloquea casi completamente la fosforilación y consiguiente activación 
de los receptores tirosina kinasa ErbB y, de este modo, juega un papel supresor del 
crecimiento tumoral en células humanas de cáncer de mama que expresan estos 
receptores (Pignatelli et al., 2001). 
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3.2.- Ligandos de PPARγ  
PPARγ puede ser activado por la unión de una amplia variedad de ligandos 
hidrofóbicos. Entre los activadores naturales de PPARγ  se encuentran los ácidos grasos 
insaturados, componentes de la dieta que, en términos generales, son buenos activadores 
de todos los subtipos de PPAR, especialmente en el caso de los ácidos grasos 
insaturados de 18-20 carbonos. Sin embargo, la mayor activación de PPARγ se logra 
por unión del eicosanoide endógeno 15-deoxi-Δ12-14-Prostaglandina J2 (15d-PGJ2), que 
tiene efectos antiproliferativos en varios tipos de carcinoma. También existen moléculas 
sintéticas capaces de activar PPARγ significativamente. Este grupo de activadores 
sintéticos incluye el grupo de sensibilizadores a insulina conocido como 
tiazolidinedionas (TZDs) y los compuestos anti-inflamatorios no esteroideos (NSAIDs). 
 
3.2.1.- Tiazolidinedionas (TZDs) 
Las tiazolidinedionas (TZDs) son sensibilizadores a insulina que mejoran la captación 
de glucosa y disminuyen la hiperglucemia y la hiperinsulinemia. Por ello han sido 
utilizados en el tratamiento contra la diabetes mellitus tipo II, a pesar de que algunos 
datos sugieren que pueden incrementar el riesgo de fallo cardiaco (Home et al., 2009).  
 
Se ha descrito que este grupo de ligandos sintéticos de PPARγ que incluye, entre otros, 
rosiglitazona, pioglitazona, ciglitazona y troglitazona, inhibe el crecimiento y promueve 
la apoptosis en distintos carcinomas. La activación de PPARγ por rosiglitazona, por 
ejemplo, inhibe el crecimiento celular y/o induce apoptosis en cáncer de próstata, 
hepatocelular y mamario (Grommes et al., 2004). Efectos similares han sido observados 
tras el tratamiento con pioglitazona en cáncer gástrico y de mama (Sohda et al., 1990). 
La troglitazona, a su vez, posee efectos antineoplásicos en una gran variedad de 
tumores, tanto in vitro como in vivo. En lo que concierne al cáncer de mama, la 
troglitazona inhibe la proliferación de las células de carcinoma mamario (Elstner et al., 
1998) y causa regresión o estasis de tumores mamarios en rata (Pighetti et al., 2001). 
Por el contrario, un ensayo clínico en fase II llevado a cabo en pacientes con cáncer de 
mama refractario avanzado no vislumbró beneficio alguno tras el tratamiento con 
troglitazona (Burstein et al., 2003). Sin embargo, hemos de tener en cuenta que este 
estudio terminó anticipadamente ya que la troglitazona fue retirada del uso clínico al 
apreciarse eventos adversos de toxicidad hepática severa.  
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3.2.2.- Tiadiazolidinonas (TDZDs) 
Los compuestos de la familia de las tiadiazolidinonas (TDZDs) poseen estructura 
similar a la del grupo de los ligandos de PPARγ TZDs, que incluye rosiglitazona y 
pioglitazona entre otros. Aunque estos compuestos fueron desarrollados inicialmente 
como inhibidores no competitivos de GSK-3β (Martinez et al., 2002), datos obtenidos 
por nuestro grupo indican que son activadores eficientes del receptor PPARγ. Además, 
nuestros datos muestran que inhibidores de  PPARγ bloquean los efectos llevados a 
cabo por las TDZDs, sugiriendo que la activación de estas está mediada por este 
receptor (Luna-Medina et al., 2005). Por otro lado, se ha demostrado que las TDZDs 
tienen potentes efectos anti-inflamatorios, entre ellos la regulación negativa de la 
ciclooxigenasa tipo 2 (COX-2), una propiedad que también posee el ligando natural de 
PPARγ 15d-PGJ2. 
 
 
Aunque tanto nosotros como otros grupos hemos descrito que las TDZDs promueven 
efectos citoprotectores en varios tejidos (Luna-Medina et al., 2007), se ha demostrado 
recientemente que uno de estos compuestos, conocido como TDZD-8, causa la muerte 
de células madre de leucemia (Guzman et al., 2007), sugiriendo una posible uso de este 
compuesto en terapia contra el cáncer. 
 
3.2.3.- Compuestos Anti-Inflamatorios No Esteroideos (NSAIDs) 
Los compuestos anti-inflamatorios no esteroideos (NSAIDs) como el indometacino, 
ibuprofeno, fenoprofeno y ácido flufémico son inhibidores de la ciclooxigenasa que 
también se unen y activan PPARγ in vitro a altas concentraciones, provocando 
diferenciación terminal de adipocitos (Lehmann et al., 1997). Algunos de ellos también 
son activadores de PPARα, capaces de inducir actividad peroxisomal en hepatocitos. 
 
Figura 4. Estructura de los compuestos tiadiazolidinonas NP00111 y NP01138 y de la 
tiazolidinediona rosiglitazona. 
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 La 15d-PGJ2 posee un papel muy importante en la adipogénesis, puesto que es un 
inductor de la diferenciación de adipocitos (Forman et al., 1995; Kliewer et al., 1995). 
Por otro lado, la 15d-PGJ2 es un potente agente inductor capaz de reprimir la expresión 
de la sintasa inducible de óxido nítrico (iNOS), el factor α de necrosis tumoral (TNFα) y 
COX-2 en monocitos activados (Ricote et al., 1998), al mismo tiempo que inhibe la 
producción de citoquinas inflamatorias (Jiang et al., 1998). Además, la 15d-PGJ2 
promueve la producción plaquetaria (O'Brien et al., 2009) y protege del estrés oxidativo. 
 
Se ha descrito que 15d-PGJ2 posee importantes efectos antineoplásicos in vitro e in vivo 
en varios tipos de cáncer, como el carcinoma de próstata, el cáncer gástrico, el 
carcinoma de colon, el glioma, el carcinoma mamario y el pancreático (Grommes et al., 
2004). Estos efectos incluyen la inhibición del crecimiento y la apoptosis, y, en algunos 
casos, se ha descrito que esta prostaglandina causa parada del ciclo celular mediante 
reducción de la cantidad de ciclina D1. En los últimos años 15d-PGJ2 ha emergido 
como un inhibidor de angiogénesiss (Fu et al., 2006) y se ha establecido que la 
inducción de apoptosis por 15d-PGJ2 es causada por la activación de p53 (Ho et al., 
2008). De acuerdo con todos estos datos, nuestro grupo ha demostrado recientemente 
que 15d-PGJ2 inhibe la proliferación de células de cáncer de mama, induce su apoptosis 
y causa malfuncionamiento de la mitocondria, lo que indica que el efecto antineoplásico 
de 15d-PGJ2 puede ser debido a múltiples mecanismos (Pignatelli et al., 2005). 
 
Algunos de los efectos anticancerígenos ejercidos por 15d-PGJ2 se basan en su 
capacidad de activar PPARγ. Sin embargo, otros efectos no están mediados por PPARγ, 
sino que son debidos a la capacidad de 15d-PGJ2 de interaccionar directamente con 
otras proteínas. La presencia de dos centros electrofílicos altamente reactivos en 15d-
PGJ2 permite la formación de aductos covalentes mediante reacciones de adición de 
Michael con nucleófilos tales como los grupos tiol de las cisteínas presentes en las 
proteínas (Kim and Surh, 2006). Por este mecanismo 15d-PGJ2 se une a varios factores 
de transcripción, tales como el factor nuclear kB (NF-kB) (Straus et al., 2000) y la 
subunidad β del complejo IKB kinasa (IKK) (Rossi et al., 2000), regulando así su 
actividad transcripcional. De modo similar, 15d-PGJ2 interacciona con transductores de 
señales celulares, interfiriendo de este modo en vías centrales de señalización. Tal es el 
caso, entre otros, de H-Ras, a quien 15d-PGJ2 se une directamente, induciendo su 
activación (Oliva et al., 2003). 
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4.- Homólogos del oncogen de leucemia eritroblástica viral (ErbBs) 
La familia de proteínas ErbB son receptores transmembrana con actividad tirosina 
kinasa intrínseca en su dominio intracelular, la cual les permite transferir grupos fosfato 
a residuos de tirosina de sustratos celulares. Esta familia toma su nombre de la 
homología de uno de sus miembros con el producto del gen de eritroblastoma viral, v-
erbB, y agrupa cuatro receptores (ErbB1-4, también denominados HER1-4). Estos 
receptores cuentan con varios ligandos extracelulares, que poseen un dominio 
conservado del factor de crecimiento epidérmico (EGF) (Hynes and Lane, 2005). 
Dichos ligandos se clasifican en tres grupos: 
· EGF, factor de crecimiento transformante α y anfirregulina, que se unen a ErbB1. 
· Betacelulina, EGF de union a heparina y epirregulina, que se unen a EGFR y ErbB4. 
· Neurregulinas (NRG), que se unen a ErbB3 y ErbB4  (NRG1 y NRG2) o sólo a ErbB4 
(NRG3 y NRG4). 
 
Los receptores ErbB existen como monómeros transmembrana inactivos. Se expresan 
en varios tipos de tejido epitelial, mesenquimal y de origen neural. La unión de ligando 
a su dominio extracelular inicia un cambio conformacional en el receptor que ocasiona 
su homo o heterodimerización. Entonces, casa miembro del dímero usa su dominio 
tirosina kinasa intracelular para fosforilar al otro, induciendo así su activación (Citri and 
Yarden, 2006). Curiosamente, ni ErbB2 ni ErbB3 no son autónomos: no se ha 
identificado ningún ligando para ErbB2 y ErbB3 carece de actividad kinasa. A pesar de 
esta falta de autonomía, tanto ErbB2 como ErbB3 forman con otros ErbBs complejos 
heterodiméricos que son capaces de generar potentes señales celulares. De hecho, 
pueden heterodimerizar entre ellos para formar el complejo ErbB2/ErbB3 que da lugar a 
una de las señales oncogénicas más potentes que se han descrito (Holbro et al., 2003a). 
 
ErbB1, ErbB2 y ErbB3 están implicados en el desarrollo y la progresión del cáncer. Los 
pacientes con cáncer cuyos tumores tienen alteraciones en receptores ErbB tienen 
tendencia a una enfermedad más agresiva, y correlaciona con un mal pronóstico. El 
papel de ErbB4 en oncogénesis no es tan evidente. Los datos actuales parecen indicar 
que este receptor está implicado en la inhibición del crecimiento celular más que en la 
proliferación. 
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.- ErbB1 
ErbB1 une múltiples ligandos, aunque su capacidad para unir el factor de crecimiento 
epidérmico (EGF) ha hecho que este receptor sea comúnmente denominado receptor del 
factor de crecimiento epidérmico (EGFR). Al unirse el ligando, ErbB1 puede formar 
homodímeros así como tres heterodímeros funcionales. Estudios de supresión de los 
genes que codifican para ligandos específicos de ErbB1 han demostrado la existencia de 
una marcada redundancia funcional entre estos ligandos. Así, ratones carentes de EGF 
no muestran ningún fenotipo, y las alteraciones en los ratones carentes de factor de 
crecimiento transformante α (TGF-α) se limitan a anomalías en los ojos. 
 
La amplificación génica que causa sobre-expresión de ErbB1 es frecuente en cánceres 
humanos, junto a mutaciones y deleciones que conllevan actividad kinasa constitutiva 
(Holbro et al., 2003b). Lo que es más, en muchos tumores factores de crecimiento 
relacionados con EGF son producidos por las propias células tumorales o por las células 
del estroma circundante, causando la activación constitutiva de ErbB1. La señalización 
de ErbB1 incrementada aberrantemente ha sido descrita en glioblastomas, carcinoma de 
pulmón, cáncer de próstata, carcinoma mamario y tumores gastrointestinales. 
 
.- ErbB2 
ErbB2 (también denominada neu o HER2) es receptor con el que heterodimerizan 
preferencialmente los otros miembros de la familia ErbB. Aunque no se ha identificado 
ningún ligando directo de este receptor, se halla en un estado conformacional que le 
predispone a la heterodimerización. Los heterodímeros que contienen ErbB2 tienen una 
mayor afinidad y especificidad que otros complejos, y el heterodímero ErbB2/ErbB3 
está considerado como el complejo ErbB más potente en lo que se refiere a fuerza de 
interacción, fosfoorilación en tirosina, y señalización (Baselga and Swain, 2009). 
 
La amplificación de ErbB2 y su sobre-expresión han sido descritas en cáncer de ovario, 
carcinoma gástrico, tumores de glándula salivar y en el 20-30% de los cánceres de 
mama (Slamon et al., 1989). Además, este patrón de expresión está asociado a un mal 
pronóstico. La sobre-expresion promueve la dimerización espontánea de ErbB2 en 
ausencia de ligando y la activación constitutiva del receptor, dando lugar a una 
señalización mediada por ErbB2 aberrantemente elevada, lo que promueve la 
tumorigénesis. En consonancia con esto, resultados de nuestro grupo indican que la 
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proliferación y la supervivencia de las células humanas de cáncer de mama son debidas 
a la activación de las cascadas de señalización de la fosfatidilinositol 3-kinasa (PI3K) y 
la proteína kinasa activada por mitógenos (MAPK), respectivamente, como resultado de 
la señalización mediante el heterodímero ErbB2/ErbB3 (Pignatelli et al., 2001). 
 
.- ErbB3 
ErbB3 pude unir cuatro diferentes ligandos, pero carece de actividad tirosina kinasa 
intrínseca, ya que es incapaz de unir adenosíntrifosfato (ATP). Esta es la razón por la 
cual ErbB3 no puede homodimerizar. Aun así, el dominio citoplásmico de ErbB3 es 
fosforilado en tirosina cuando el receptor heterodimeriza, y esto permite el 
reclutamiento y la activación de PI3K, que promueve la proliferación tumoral. ErbB3 es 
el monómero preferido para la dimerización cuando la señalización ocurre mediante la 
vía de PI3K, probablemente porque aunque ErbB1 y ErbB2 pueden interaccionar y 
activar PI3K a través de proteínas adaptadoras, la unión mediante ErbB3 es directa y la 
activación resultante de la vía de PI3K es más intensa (Hellyer et al., 1998). 
 
Alteraciones en la señalización por ErbB3 han sido descritas en cáncer de mama, 
ovario, pulmón y próstata, entre otros. En todos estos casos, pero especialmente en 
cáncer de mama, ErbB3 es expresado generalemente junto a ErbB2 (Lee-Hoeflich et al., 
2008). La amplificación de ErbB3 ha sido observada en cáncer de pulmón y cada vez un 
mayor número de datos indican que la expresión de ErbB3 puede ser incrementada para 
compensar la inhibición de otros miembros de la familia ErbB (Sergina et al., 2007). 
 
.- ErbB4 
ErbB4 muestra una gran similitud con ErbB1 en la especificidad de ligandos y en el 
reclutamiento de proteínas adaptadoras una vez iniciada la señalización. Aunque ErbB4 
actúa principalmente como un receptor tirosina quinasa en procesos de señaización en 
membrana plasmática, también es capaz de sufrir un procesado proteolítico que genera 
una chaperona que facilita la traslocación de ciertos factores de trascripción como el 
factor de transcripción activador de la transpcripción y transductor de la señal 5 
(STAT5) al núcleo (Williams et al., 2004). Estudios recientes de las todavía poco 
conocidas funciones de ErbB4 indican que la supresión de su función conduce a la 
inhibición del crecimiento celular en cáncer de mama (Hollmen et al., 2009). 
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5.- PROTEINAS FOSFOTIROSINAS FOSFATASAS 
Las proteínas fosfotirosinas fosfatasas (PTPs) son proteínas encargadas de defosforilar 
residuos de tirosina. Dado que la fosforilación en tirosina de proteínas es un evento 
clave en la activación de cascadas de señalización, las PTPs constituyen un mecanismo 
regulatorio esencial en la modulación de señales (Tonks, 2006). En el caso de la 
señalización mediada por ErbB, varias fosfatasa han sido implicadas en la regulación de 
la vía, una característica que se basa en la presencia en la fosfatasa de dominios capaces 
de reconocer y unir tirosinas fosforiladas. Este es el caso de los dominios tipo 2 de 
homología a Src (SH2) y de unión a fosfotirosina (PTB). Así, por ejemplo, EGFR es 
unido y defosforilado por la fosfatasa PTP1B, RPTPσ, la fosfatasa 1 de densidad 
incrementada (DEP1) y la fosfatasa 1 con dominios SH2 (SHP-1) (Ostman and Bohmer, 
2001), mientras que ErbB2 es defosforilada por la fosfatasa 1 derivada de cerebro con 
motivo PEST (BDP1) (Gensler et al., 2004) y regulada positivamente por la fosfatasa 2 
con dominios SH2 (SHP-2) (Zhou and Agazie, 2009). 
 
.- SHPs 
Las SHPs son una familia de fosfatasas de tirosina citosólicas que poseen dominios 
SH2. Esta familia agrupa a las fosfatasas SHP-1, SHP-2, corkscrew (Csw) de 
Drosophila y PTP-2 de Caenorhabditis elegans. SHP-1 y SHP-2 tienen una alta 
homología en su estructura primaria (55% de semejanza). Ambas cuentan con dos 
dominios SH2 y un dominio proteína tirosina fosfatasa seguido de una cola C-terminal 
básica que contiene sitios de fosforilación (Tyr536 y Tyr564 para SHP-1) y determina la 
identificación del sustrato y la actividad (Pei et al., 1994; Zhang et al., 2003). 
Curiosamente, esta región reguladora C-terminal es la zona donde SHP-1 y SHP-2 
presentan una menor homología de secuencia (en torno al 15%), un hecho que podría 
explicar sus divergencias en distribución, función y dianas. A pesar de su estructura 
similar, SHP-1 y SHP-2 difieren enormemente en su distribución en la célula y en su 
función biológica. SHP-1 se expresa abundantemente en células hematopoyéticas y 
epiteliales, y se comporta como un regulador negativo de varios receptores tirosina 
kinasa. En cambio, SHP-2 se expresa ubicuitamente en células con diverso origen y 
actúa como un regulador positivo (Plutzky et al., 1992), con funciones que antagonizan 
las de SHP-1 en algunos casos (Qu et al., 2001). 
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SHP-1 
SHP-1, también conocida como PTP1C, SH-PTP1, HCP y PTPN6 está presente bajo 
diferentes isoformas en células hematopoyéticas y epiteliales (Poole and Jones, 2005), 
donde actúa como un regulador negativo de la señalización celular. De hecho, SHP-1 
juega un papel clave en antagonizar las señales promotoras de crecimiento iniciadas por 
tirosina kinasas, puesto que ratones carentes de proteína SHP-1 muestran 
hiperproliferación de progenitores mieloides y linfoides así como una mayor respuesta 
ante factores de crecimiento (Tapley et al., 1997). Además, la cantidad de RNA 
mensajero (RNAm) y proteína de SHP-1 se encuentra disminuida en la mayoría de 
linfomas y leucemias (Oka et al., 2001), y la expresión forzada de SHP-1 en líneas 
celulares de linfoma y leucemia causa una reducción de su proliferación (Bruecher-
Encke et al., 2001). Resultados similares se han obtenido en otros tipos de cáncer, 
incluyendo el cáncer de mama, donde la transfección de SHP-1 inhibe el crecimiento de 
la línea celular carente de SHP-1 HTB26 (Wu et al., 2003), confirmando de este modo 
la implicación de esta fosfatasa en la oposición al crecimiento celular. En células de 
cáncer de mama, SHP-1 defosforila varios receptores tirosina kinasa, como EGFR 
(Tomic et al., 1995), el receptor de crecimiento derivado de plaquetas (PDGF) (Yu et 
al., 1998) y ErbB2 (Vogel et al., 1993), lo que sugiere que el efecto antiproliferativo de 
la fosfatasa guarda relación con el silenciamiento de vías de señalización iniciadas por 
estos receptores. De hecho, la sobre-expresión de SHP-1 conduce a una reducción de la 
fosforilación de EGFR y viceversa (Keilhack et al., 1998). 
 
Una peculiaridad de SHP-1 es que la fosforilación de su región C-terminal determina su 
activación. La fosforilación de SHP-1 en Tyr536 por el receptor tirosina kinasa de 
insulina se ha demostrado que induce su activación (Uchida et al., 1994). De modo 
similar, SHP-1 experimenta un aumento de su actividad catalítica al ser fosforilada en 
tirosina por Src (Frank et al., 2004) y en plaquetas humanas al ser fosforilada a la vez en 
residuos de tirosina y serina (Li et al., 1995).  La cola C-terminal de SHP-1 también 
posee una secuencia de localización nuclear, que está bloqueada en la proteína nativa 
pero se activa al ser estimulada con EGF y causa la traslocacion de SHP-1 del citosol al 
núcleo en células embrionarias de riñón de mono (He et al., 2005) y en varias líneas 
celulares de cáncer estudiadas (las líneas de carcinoma epitelial humano A431 y de 
adenocarcinoma humano de colon HT29), de manera independiente de estimulación con 
EGF. 
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SHP-2 
A pesar de su similitud de secuencia, SHP-2 (PTP1D, PTP2C, SH-PTP2, Syp o 
PTPN11) ejerce funciones antagónicas a las de SHP-1. Se ha descrito que SHP-2 
interacciona directamente con varios receptores tirosina kinasa como EGFR y ErbB2 y 
actúa como regulador positivo de su señalización, promoviendo de este modo el 
crecimiento y la supervivencia celular en diferentes tipos celulares. De hecho, su 
activación es un requisito en ciertos sistemas para lograr la activación de las vías de 
PI3K y MAPK (Wu et al., 2001). Además, se ha descrito que SHP-2 promueve la 
transformación celular (Agazie et al., 2003) mediante la regulación positiva de la 
señalización por ErbB2 (Zhou and Agazie, 2009). 
 
.- BDP1 
BDP1 es una fosfatasa rica en  secuencias PEST, que se caracterizan por su alto 
contenido en prolina (P), ácido glutámico (E), serina (S) y treonina (T). Se ha descrito 
que BDP1 regula negativamente la activación de ErbB2 en líneas celulares de cáncer de 
mama, lo que causa una reducción en la activación de MAPKs  (Gensler et al., 2004). 
 
6.- CANCER STEM CELLS 
Tradicionalmente se consideraba que el cáncer seguía un modelo de evolución clonal, 
por el cual mutaciones estocásticas se acumulan a lo largo del tiempo en una célula o 
grupo de ellas, confiriendo a estas células una ventaja proliferativa sobre el tejido 
adyacente, lo que favorece su expansión en la selección natural por competición. 
Consecuentemente, cualquier célula tiene el potencial de originar un tumor. Sin 
embargo, cada vez hay más datos que apoyan que el cáncer sigue un modelo de célula 
madre, según el cual la tumorogénesis viene dada por un grupo de células con potencial 
proliferativo ilimitado debido a su capacidad de división asimétrica, por la cual generan 
una célula copia exacta de sí mismas (auto-renovación) y otra célula hija que diferencia. 
Así pues, las células de un tumor son funcionalmente heterogéneas, ya que sólo unas 
pocas son responsables de la progresión del tumor. Aunque ambos modelos no son 
mutuamente excluyentes, estudios de trasplante de células aisladas en ratones 
inmunosuprimidos indican que sólo células que expresan un determinado patrón de 
marcadores e superficie son capaces de regenerar el tumor entero (Bhatia et al., 1997). 
Estas células madre de cáncer han sido descritas en varias neoplasias tras estudios de 
trasplantes seriados, y los antígenos de membrana que las caracterizan varían 
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dependiendo del tejido de origen. Así pues, han sido descritas como CD44+/CD24-/bajo 
en cáncer de mama (Al-Hajj et al., 2003) y como CD133+ en carcinoma de colon 
(O'Brien et al., 2007), carcinoma de pulmón y glioma (Singh et al., 2004). 
 
Junto con los xenotrasplantes, el cultivo en condiciones no adherentes ha contribuido a 
la identificación de las células madre de cáncer. Cuando son crecidas como cultivos en 
suspensión, sólo las células con propiedades de célula madre sobreviven y proliferan, 
originando esferas que representan la progenie de una sola célula madre y están 
enriquecidas en células progenitoras (Ponti et al., 2005).  Esta propiedad es compartida 
con las células madre de tejido normal, no cancerígeno (Dontu et al., 2003). 
Curiosamente, algunos estudios indican que las esferas son generadas in vitro 
principalmente por células presentes en la “side population”, una subpoblación de 
células detectada por citometría de flujo gracias a su capacidad de expulsar de manera 
diferente el compuesto fluorescente denominado Hoechst 33342, que se une al ADN 
celular. La expulsión diferencial de este compuesto radica en la sobre-expresión en estas 
células del transportador de resistencia a drogas llamado grupo de unión de ATP G2 
(ABCG2) (Goodell et al., 1996). 
 
Sin embargo, una gran controversia rodea tanto las técnicas empleadas para definir los 
marcadores como su precisión, ya que hay grandes divergencias en los resultados 
obtenidos en los modelos de xenotrasplante dependiendo de la cepa de ratón utilizada 
(Quintana et al., 2008) y de las condiciones experimentales, así como del uso de 
microambientes o matrices articificiales como Matrigel. Del mismo modo, el perfil 
CD44+/CD24-/bajo definido para las células madre de cáncer de mama no correlaciona 
con peor pronóstico, lo que ha llevado a proponer marcadores alternativos como la 
enzyma aldehídodeshidrogenasa 1 (ALDH1) (Ginestier et al., 2007). 
 
La identificación y el aislamiento de las células madre de cáncer es un desafío 
primordial en el actual horizonte científico, ya que para ser eficaces las terapias deben 
erradicar esta subpoblación de células responsable del inicio y la progresión de la 
tumorogénesis. En caso de que alguna de estas células persista tras el tratamiento el 
tumor volverá a resurgir. Por ello, la evaluación de las propiedades antitumorogénicas 
de un compuesto en la población de células madre de cáncer es de crucial importantcia 
para determinar su potencial como agente terapéutico. 
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En este trabajo hemos analizado aun más el mecanismo de acción de los ligandos de 
PPARγ en células de cáncer de mama y su efecto en la población de células madre de 
cáncer. 
  
 
 
 
 
 
 
 
 
 
 
 
 
OBJECTIVES 
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OBJECTIVES  
 
 
 
1.- Assessment of the effects of PPARγ ligands 15-deoxi-Δ12-14-Prostaglandin J2, 
rosiglitazone and pioglitazone on viability, proliferation and apoptosis of human 
breast cancer cells. 
 
2.-  Evaluation of the effects of thiadiazolidinones (TDZDs) on growth of human 
breast cancer cells. 
 
3.- Study and characterization of the mechanism of action of 15d-Prostaglandin J2 
on ErbB2 and ErbB3 dephosphorylation. 
 
4.- Study and characterization of the mechanism of action of 15d-Prostaglandin J2 
on cell cycle progression and microtubule dynamics. 
 
5.- Evaluation of the antitumorigenic effects of PPARγ ligands on human breast 
cancer stem cells. 
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MATERIALS AND METHODS   
 
Cell culture 
MCF-7, MDA-MB-231, SKBR3 and T47D human breast cancer cell lines were 
obtained from American Type Culture Collection (ATCC) (catalogue numbers HTB-22, 
HTB-26, HTB-30 and HTB-133, respectively). MCF-7, MDA-MB-231 and SKBR3 
cells are derived from pleural effusions of breast adenocarcinomas, whereas T47D 
derives from pleural effusion of a ductal carcinoma. All cell lines were cultured in 
Roswell Park Memorial Institute (RPMI) medium (Gibco, Invitrogen, CA, USA) 
supplemented with 2mM glutamine, 40 μg/mL gentamicin, 0.5 μg/μL fungizone and 
10% fetal bovine serum (FBS) (Gibco, Invitrogen, CA, USA) at 37ºC and 5% CO2.  
 
Drug administration 
Experimental cultures were usually grown in regular 10% FBS RPMI or in regular 
RPMI supplemented with 5% dextran-charcoal stripped FBS. After 24 hours of growth 
in these conditions, cells were submitted to the treatments specified in Table 1. 
Drug Abbreviation Supplier Reference Working 
concentration
15-deoxi-Δ12,14-
prostaglandin J2
15d-PGJ2
Cayman Chemical 
MI, USA 18570 10 μM
Human Neuregulin-β1 NRG1
Peprotech Inc., NJ, 
USA 100-03 30 nM
Nocodazole ----- Sigma-Aldrich Co., MO, USA M1404 1 μM
Pioglitazone PGZ Actos. Lilly. London, UK ----- 10 μM
Rosiglitazone RSG
Cayman Chemical 
MI, USA 71740 30 μM
TDZD-8 ----- Sigma-Aldrich Co., MO, USA T8325 10 μM
NP00111
NP01138
NP031112
NP031115
NP031122
----- Noscira, SPAIN 10 μM
 
Table 1.- List of treatments administered in the study and working concentrations. 
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Cell viability 
Cell viability was measured using the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl 
tetrazolium bromide (MTT) assay (Roche Diagnostic GmbH, Basel, Switzerland), based 
on the ability of viable cells to reduce yellow MTT to blue formazan. Cells were 
cultured in 96-well microtitre plates (8,000 cells/well) and exposed to drugs during 
different periods of time. Then, cells were incubated with MTT (0.5 mg/mL, 4 hours) 
and subsequently solubilized in 5% DMSO/5 mM HCl for at least 2 hours at dark. MTT 
reduction was quantified by absorbance measurement at 550 nm. 
 
Proliferation assay 
Cells were seeded onto 96-well plates at a density of 8,000 cells/well. After 24 hours of 
growth in normal medium, cells were switched to RPMI containing 5% dextran-
charcoal stripped FBS and grown for 24 hours after which drugs were added. Cells were 
grown for 24 hours in the presence of 0.5 mCi radiolabelled [3H]thymidine and 
harvested. [3H]radioactivity was measured in a solid scintillation counter.  
 
Alternatively, a colorimetric assay based on incorporation of the thymidine analogue 5-
Bromo-2-deoxy-uridine (BrdU) was used. Briefly, 8,000 cells/well are plated in a 96-
well culture plate and switched after 24 hours of growth to medium supplemented with 
5% stripped FBS. Treatments are then added and, after incubation for further 24 hours, 
DNA synthesis is assayed with the ELISA BrdU Assay Kit (Roche Diagnostic GmbH, 
Basel, Switzerland) according to the manufacturer’s guidelines. Absorbance 
measurements were obtained using a Varioscan (Thermo Electron Corp.) plate reader. 
 
Apoptosis assay 
To calculate the extent of cell death, 0.5x106 cells were grown in RPMI for 24 hours 
before switching to medium supplemented with 5% stripped-FBS for another 24 hours 
previous to the addition of the corresponding treatments. For analyses, both the floating 
cells in the supernatant and the adhered ones were collected from each plate. Apoptotic 
cells were assayed by analyzing annexin-V conjugated to fluoresceinisothiocyanate 
(annexin-V-FITC) (Bender MedSystems, Vienna, Austria) to determine the 
translocation of phosphatidylserine from the inside to the outside of the plasma 
membrane. Cell staining was performed according to the manufacturer’s instructions.  
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Cell cycle analysis 
MCF-7 cells treated with 10 μM 15dPG-J2 or 30 μM rosiglitazone in RPMI medium for 
24 hours were fixed in 70% ethanol/phosphate buffer saline (PBS), pelleted and 
resuspended in buffer containing 10 μg/ml RNAse A and 0.01 mg/ml propidium iodide 
(PI). Cell cycle distribution was determined by flow cytometric analysis in a Cyan 
MLE-R cytometer (DAKO-Cytomation, Glastrup, Denmark). Data analysis was 
performed using the Summit Software (DAKO). 
 
Activation of human PPRE 
Semiconfluent cultures were transfected with the reporter plasmid pPPRE-tk-luc, 
containing three PPARγ consensus binding sites upstream of a minimal promoter. 
Transfection was performed using Lipofectamine2000 (Gibco, Invitrogen, CA, USA) 
according to the manufacturer’s protocol. Cells received 0.2 μg of luciferase reporter 
plasmid and were harvested 24 hours after treatment with 10 or 20 μM 15d-PGJ2 or 
TDZD-8, for determination of luciferase and β-galactosidase (to assess transfection 
efficiency) activities. Each experiment was repeated at least three times in triplicate.  
 
Soft agar colony assays 
Anchorage-independent growth was determined by suspending 50,000 cells in 0.3% 
Noble Agar (Sigma-Aldrich Co., MO, USA) in 10% FBS RPMI medium in 60 mm 
plates over a bottom layer of 0.5% agar in medium. Cells were allowed to grow for 20 
days with feeding every 2.5 days. At this time, NRG1 and 15d-PGJ2 were added where 
appropriate. Colonies were stained with p-iodotetrazolium violet. Experiments were 
carried out three times in duplicate. 
 
Western-Blot 
Cells were washed twice with ice-cold PBS, and detached from the culture dish with a 
cell scraper in presence of 175 μL (for a 6-cm diameter plate) of extraction buffer (PBS 
containing 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate 
[SDS] and 1mM phenylmethylsulphonyl fluoride [PMSF], 1mM sodium orthovanadate 
and 0.1 mM sodium pyrophosphate). Cells were then disrupted by repeated aspiration 
through a 21-gauge needle, incubated on ice for 30 min and spun at 12,000 g for 20 
min. Supernatants were separated and 20 micrograms of total cellular protein were 
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loaded onto each lane of a 10% SDS-polyacrilamide gel. After electrophoresis, proteins 
were transfered to Protran nitrocellulose membranes (Whatman, NJ, USA) at 90 mA 
overnight in transfer buffer (25 mM Tris, pH 8.3; 190 mM glycine; 20% methanol; 
0.5% SDS). Protein loading and transference were checked by Red Ponceau staining. 
Blots were then blocked with 5% dry non-fat milk or 3% bovine serum albumin (BSA) 
in Tris-buffered saline (TBS) (20 mM Tris-HCl, pH 7.6; 130 mM NaCl; 0.1% Tween-
20) containing 0.5% Tween-20 for 60 min and probed with appropiate antibodies (see 
Table 2). After washing, membranes were incubated with peroxidase-conjugated 
secondary antibodies and immunoreactive bands were visualized using the Amersham 
enhancement chemiluminiscence system (ECL) (GE Healthcare, Buckinghamshire, 
UK). Blots were reprobed with different antibodies after stripping for 30 min in a buffer 
of 62.5 mM Tris-HCl (pH 6.7), 100 mM β-mercaptoethanol and 2% SDS. 
 
Antibodies 
Antibody Origin Clonality Reference Manufaturer
Alexa various Vector Laboratories, CA, USA
BDP-1 rabbit polyclonal ----- Donated by Dr. Axel Ullrich
Biotin goat polyclonal BA9500 Vector Laboratories, CA, USA
CD24:PE mouse monoclonal 555428 BD Pharmingen
CD44:FITC mouse monoclonal 555478 BD Pharmingen
ErbB2 mouse monoclonal 610161 BD Transduction Laboratories
Pericentrin rabbit polyclonal PRB-432C Covance, CA, USA
RC-20:HRPO mouse monoclonal 610023 BD Transduction Laboratories
SHP-1 rabbit polyclonal SC-287 Santa Cruz Biotechnology Inc.
SHP-2 rabbit polyclonal SC-424 Santa Cruz Biotechnology Inc.
α-tubulin mouse monoclonal T9026 Sigma, MO, USA
β-tubulin mouse monoclonal T8660 Sigma, MO, USA
Table 2. Antibodies used in western-blot, immunoprecipitation and microscopy.  
 
Quantitative-PCR (Q-PCR) 
In order to detect changes in SHP-1, SHP-2 and BDP1 mRNA expression, MCF-7 cells 
treated or not for 24 hours with 15d-PGJ2 were lysed in guanidinium thiocyanate to 
proceed with RNA extraction with phenol chloroform. Quality and concentration of the 
RNA obtained was determined in an Agilent 2100 bioanalyzer (Agilent Technologies, 
CA, USA) and cDNA synthesis was performed using Moloney Murine-Leukaemia 
Virus Reverse Transcriptase (M-MLV RT) in the presence of random nucleotide 
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hexamers. Q-PCR was performed in an ABI PRISM 7900HT Fast Real-Time PCR 
(Applied Biosystems, CA, USA) and results were analyzed with SDS software using 
measurements of ribosomal 18S mRNA transcription as loading control. For 
amplification, Power SYBR Green PCR Master Mix (Applied Biosystems, CA, USA) 
was used, together with the following primers for each phosphatase: 
BDP1:  5’-GAACGTGAGGAAGAACCGCTA-3’ (forward) 
 5’-CGCGTCTGATCATAAGGCAG-3’ (reverse) 
SHP-1: 5’-ACTTCTCGCTCTCCGTCAGG-3’ (forward); 
 5’-GGATCCGAATATGGGTCACCT-3’ (reverse) 
SHP-2: 5’-CCTGCCCTTTGATCATACCAG-3’ (forward) 
 5’-TCATTGGGATCACCATCGTG-3’ (reverse) 
 
Immunoprecipitation 
For immunoprecipitation assays, 600,000 cells were grown for 24 hours in complete 
medium, switched to serum-treated medium and exposed for different time to 15d-PGJ2 
(Cayman Chemical, MI, USA). Cells were then stimulated with NRG1 (30 nM) for 5 
minutes, lysed in 500 ml of PBS containing 1% NP40, 0.5% sodium deoxycholate, 
0.1% SDS and protease inhibitors, and spun at 12,000 g for 20 minutes. Protein 
concentration in the supernatant was determined by Bradford assay and equal amounts 
of protein from each sample were collected, precleared with Pansorbin (Calbiochem-
Novabiochem Corp.) and incubated for 12 hours at 4°C with 1 μg of the appropriate 
antibodies (see Table 2). Protein-A-Sepharose was added to each sample and 
additionally incubated for 5 hours at 4°C. Beads were collected by microcentrifugation 
and washed five times with lysis buffer. Immunocomplexes were eluted by boiling for 3 
min in SDS sample buffer (100 mM Tris, pH 6.8, 36% glycerol, 4% SDS, 0.01% 
bromophenol blue and 200 mM DTT) and subjected to SDS-PAGE. Proteins were then 
transferred to nitrocellulose membranes. The blots were blocked with 3% BSA in TBS-
Tween buffer for 1 hour at room temperature and incubated with the horseradish 
peroxidase-coupled antiphosphotyrosine antibody RC-20 (Transduction Laboratories, 
Lexington, KY, USA) used at 1:2500 dilution in TBS-Tween with 3% BSA for 2 hours. 
After several washes, immunoreactive bands were visualized using Amersham ECL 
detection kit. Membranes were stripped and incubated with the corresponding 
antibodies for loading control. 
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Transfection of interference RNA (iRNA). 
Semi-confluent MCF-7 cells were transfected using Lipofectamine2000 (Gibco, 
Invitrogen, CA, USA) according to the manufacturer’s recommendations. Transfected 
iRNAs included a siGLO-RNA tagged with enhanced green fluorescent protein (EGFP) 
(Dharmacon, CO, USA; Catalogue number D-001630-01-05) that was used as a control 
of transfection efficiency, a non-targeting iRNA (Dharmacon, CO, USA; Catalogue 
number D-001210-01-05) used as control, and a mixture of four iRNAs directed against 
SHP-1 phosphatase, the so-called hPTPN6 SMARTpool (Dharmacon, CO, USA; 
Catalogue number M-009778-00). Optimal final iRNA concentration was determined 
on a dose curve assay analyzing the inhibition of SHP-1 achieved by growing 
concentrations of iRNA and the resulting cellular toxicity. A working concentration of 
30 nM was probed to significantly silence SHP-1 expression without causing cell death. 
Twenty-four hours post-transfection, efficiency of iRNA incorporation was determined 
in the control plate by visual analysis in an Zeiss Axiovert 35 microscope of the ratio of 
cells showing green fluorescence due to siGLO-RNA. Efficiency was higher than 80% 
in all the experiments and fluorescence was observable for longer than 72 hours. 
Twenty-four hours after transfection, medium was shifted to RPMI supplemented with 
5% stripped-FBS and 12 hours later treatments were added where appropriate.  
 
Tyrosine phosphatase activity assay. 
SHP-1 phosphatase activity was evaluated using the Universal Tyrosine Phosphatase 
Assay Kit (Takara Bio Inc., Shiga, Japan). SHP-1 protein was immunoprecipitated from 
MCF-7 cells as previously indicated once they had been treated with 15d-PGJ2 and/or 
NRG1. Equal amounts of protein were used in the immunoprecipitation of SHP-1, and 
analysis of the phosphatase activity within each immunoprecipitate was performed 
following the manufacturer’s instructions. 
 
Immunofluorescence and confocal microscopy.  
Confocal microscopy was used to detect cytoskeleton organization. MCF-7 cells were 
plated in glass coverslips in 24-well cell culture plates and grown in regular medium for 
12 hours before switching to new medium with the corresponding treatment. Cells were 
then fixed for 10 min with methanol at –20°C, permeabilized with 0.1% Triton X-100 
for 30 min at 37ºC and washed with PBS. After one hour incubation with the 
59 
 
appropriate primary antibody (see Table 2), cells were washed and incubated with 4,6-
diamidino-2-phenylindole (DAPI), Alexa Fluor 488, Alexa Fluor 546, or Alexa Fluor 
647 secondary antibodies (Molecular Probes, OR, USA) for 45 min at 37°C. Images 
were acquired using a Radiance 2100 laser scanning confocal microscope (Bio-Rad, 
Hercules, CA) using a 60x NA 1.40 oil immersion objective (Nikon). The images were 
obtained using a series of 0.5 μm (depth) spaced cell fluorescent slices (Z axis). 
Confocal microscope settings were adjusted to produce the optimum signal-to-noise 
ratio. Images were collected and processed using Lasersharp 2000 and Adobe 
Photoshop version 8.0, respectively. 
 
For staining of mitochondria, cells were treated with 20 nM Mitotracker Red CMXRos 
(Molecular Probes, Leiden, The Netherlands) for 45 min, fixed for 10 min in methanol 
at -20ºC, and washed with PBS. Morphology was determined using a TCS SP2 laser 
scanning spectral confocal microscope (Leica Mycrosystems). 
 
Separation of soluble and polymerized tubulins. 
Separation of soluble and polymerized tubulins was carried out as described by Minotti 
et al (Minotti et al., 1991). Briefly, 12 hours after 15d-PGJ2 (10 μM) or rosiglitazone 
(30 μM) treatment, MCF-7 cells were lysed using 120 μL of microtubule-stabilizing 
buffer [20 nM Tris-HCl (pH 6.8), 1 mM MgCl2, 2 mM EGTA, 0.5% NP-40, 2 mM 
PMSF, 1 mM benzamidine]. After vortexing, 120 μg of protein were centrifuged at 
13,000 rpm for 15 minutes at room temperature and soluble (supernatant) and 
polymerized (pellet) tubulin analyzed by SDS-PAGE. 
 
Time-Lapse microscopy.  
MCF-7 cells were plated and placed in a chamber in complete medium with CO2 
exchange at 37ºC. Cells were imaged every 1 min for 1-2 days using a 40x objective on 
an inverted microscope (Zeiss Axiovert 135 TV). Images were captured on a JVC (TK-
C1481EG) digital video camera. Where indicated, 10 μM 15d-PGJ2 or 30 μM 
rosiglitazone were added to live microscopy media. Resulting movies were collected 
and processed by using image analySIS software (Soft Imaging System) and exported 
as Quicktime (Apple Computer, Cupertino, CA) and are shown at 7 frames per second. 
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In vitro tubulin polymerization assay.  
In vitro tubulin assembly was evaluated using the HTS-Tubulin Polimerization Assay 
Kit (Cytoskeleton, Denver, CO), according to the manufacturer's instructions. 
Absorbance readings were taken at 340 nm every 30 s for 1 h, using a Varioscan 
(Thermo Electron Corporation) plate reader and data was processed using the Skanit 2.0 
Research Edition software.  
 
Biotinylated 15d-PGJ2 pull down and western blot analysis.  
For assessment of in vivo incorporation of 15d-PGJ2 into α- and β-tubulin in intact cells, 
MCF-7 cells were incubated with 10 μM biotinylated 15d-PGJ2 for 2 hours, lysed in 
lysis buffer [10 mM Tris-HCl (pH 7.5), 0.1 mM ethylenediaminetetraacetic acid 
(EDTA), 0.1 mM EGTA, 0.5% SDS, 0.1 mM 2-mercaptoethanol and 1mM PMSF], and 
biotinylated proteins were purified by adsorption onto Neutravidin beads (Pierce 
Biotechnology Inc., IL, USA), as indicated by the manufacturer’s protocol. Proteins 
were detected by Western-blot using anti-α- and anti-β antibodies, as previously 
described. 
 
Off line nanospray characterization of 15d-PGJ2 by mass spectrometry (MS). 
About 1 µL containing 5 µg of 15d-PGJ2 was dissolved in 20 µl of 50% CH3CN, 0.5% 
acetic acid. 5 µL were introduced into the off line nanospray medium needle and 
infused using the Protana nanosprayTM ion source. Then, 15d-PGJ2 was ionized into a 
triple quadrupole mass spectrometer (4000 Q Trap LC-MS/MS hybrid system, Applied 
Biosystems, MDS Sciex), and data were acquired for 2 min. The needle voltage was set 
at 1300 V, and the declustering potential was set at 50 V to minimize in-source 
fragmentation. A collision energy between 25 and 30 was used to induce the 
fragmentation of the 15d-PGJ2 molecule. 
 
Protein digestion and sample preparation for MS analysis.  
Untreated or 15d-PGJ2-treated microtubules were incubated with 1 μg trypsin (Promega 
Sequencing Grade) for 2 hours at 37ºC. Reaction mixtures were dried in vacuo and 
dissolved in 5% CH3CN, 0.5% CH3COOH, for later MS analysis. 
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Nano-HPLC and tandem triple-quadrupole MS analysis of peptides. 
The tryptic peptides from control and 15d-PGJ2-treated samples were injected with a 
Famos (LC Packings) autosampler onto a PepMapTM C18 reversed phase micro-
column (300 µm ID x 5 mm) from LC Packings and washed to remove salts. Samples 
were eluted onto a C18 reversed phase nano-column (100 µm ID x 15 cm, Teknokroma, 
Mediterranea sea), which was developed with a CH3CN gradient (5-47.5% CH3CN 
over 45 min, followed by a 1 min increase to 85.5% CH3CN) generated by an Ultimate 
Nano-HPLC (LC Packings). A flow rate of ca. 300 nL min-1 was used to elute peptides 
from the nano-column to a New Objective PicoTip™ emitter nano-spray needle (3000 
V) in a Protana nanospray ion source, and ions were analyzed with the 4000 Q-Trap 
system. In the enhanced resolution mode, the linear ion trap was scanned at m/z 250/s, 
and the ion of interest was selected in Q1 by precursor ion scanning. N2 was used as the 
curtain (value of 15) and collision gas (set to high). 
 
Multiple Reaction Monitoring (MRM). 
15d-PGJ2-bound tryptic peptides from treated and untreated microtubules were analyzed 
in the MRM mode. Q1 was set on the m/z corresponding to charged parent ions from 
masses 1, 2, 3, and 4 previously observed (m/z at 644.4, 662.9, 726.4, and 989.9, 
respectively), and Q3 was set on specific fragment ions for each parent mass (m/z at 
482.3 corresponding to y4 fragment ion for mass 1, m/z at 948.2 corresponding to 15d-
PGJ2-modified y6 fragment ion for mass 2, m/z at 841.4 corresponding to y7 fragment 
ion for mass 3, and m/z 1326.1 corresponding to doubly-charged, y25 fragment ion for 
mass 4). Collision energy was set to 30 eV.  
 
MS data analysis. 
All the chromatograms and MS/MS spectra from the 4000 Q Trap System were 
analyzed with Analyst 1.4.1 software (Applied Biosystems, CA, USA). Analyses of 
15d-PGJ2-binding to microtubules by MS were repeated with two independent samples. 
 
Mammosphere culture. 
Supernatants from exponentially growing cultures in 10 cm-diameter dishes were 
centrifuged in a Selecta Centroni-BL centrifuge at 1,000 r.p.m. (700 r.c.f.) for 5 min. 
Cells were resuspended and analyzed for single-cellularity. Viability was determined 
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using Trypan Blue dye (Sigma-Aldrich Co., MO, USA). Then, 2,000 viable cells/mL 
were plated in low-attachment plates (Falcon, BD Biosciences, CA, USA) in serum-free 
medium containing DMEM-HAM’s-F12 1:1 supplemented with B27 (Gibco, 
Invitrogen, CA, USA), 20 ng/mL epidermal growth factor (EGF) and 20 ng/mL basic 
fibroblast growth factor (bFGF) (Peprotech Inc., NJ, USA). Medium was partially 
refreshed every 2.5 days, with addition of EGF and bFGF. To obtain secondary 
mammospheres, primary mammospheres were collected by centrifugation (400 r.p.m.) 
after 7-10 days, dissociated enzymatically (4 min trypsin-EDTA at 37ºC) and seeded as 
indicated. 
 
Mammosphere forming efficiency. 
To determine mammosphere forming efficiency, the number of mammospheres 
resulting from seeding 2,000 cels/mL as previously described was evaluated by direct 
observation on a Nikon Eclipse TS100 microscope.  
 
Study of primary mammosphere growth. 
Briefly, 2,000 viable cells per mL were plated in low-adherence plates as previously 
described. Mammosphere formation was followed during 12 days. Then, treatment was 
added. Treatment and growth factors were renewed each 2.5 days dissolved in medium 
to contribute to medium refreshment. After 12 days, mammospheres were counted and 
photographed. 
 
Self-renewal studies. 
Primary spheres were obtained from MCF-7 cells as previously indicated and allowed 
to grow for 5 days in non-adherent plates. Similarity in sphere number and size in the 
different wells at the beginning of the experiment was checked. Treatments were added 
where corresponding and spheres were allowed to grow for 5 additional days (days 6-
10). Then, spheres were sedimented, washed with PBS,disaggregated until single 
cellularity and resuspended in mammosphere medium containing or not the 
corresponding treatment. Spheres were grown in this medium for 5 days (day 11-15) 
and were then photographed. Treatment and growth factors were renewed each 2.5 
days.  
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Detection of CD44+/CD24-/low expression profile by flow cytometry. 
Typically, 600,000 cells from each cell line were plated in 10-cm diameter culture 
dishes in regular RPMI medium. Then, 24 hours later, supernatants were collected, and 
adherent cells were trypsinized for 3 min and included in the tube containing the 
corresponding supernatant. Cells were centrifuged at 1,000 r.p.m. 5 min and the pellet 
was then washed with PBS. Cells were counted and 106 cells were separated, 
centrifuged and resuspended in 100 μL PBS 1% FBS. Samples were incubated at dark 
with CD44 monoclonal antibody coupled to FITC (BD Pharmingen; cat.# 555478) and 
CD24 antibody coupled to APC (BD Pharmingen; cat.# 555428) for 15 min at room 
temperature with moderate shacking. Samples were centrifuged and washed with PBS 
before being analyzed in a MoFlo cytometre (Beckman-Coulter, CA, USA). Controls 
for each dye and cell type were included. To avoid divergences in the detection of the 
membrane antigens due to their enzymatic cleavage by trypsin, control plates where 
cells were detached using EDTA or Versene (Gibco, Invitrogen, CA, USA) were used, 
obtaining similar results than with trypsin.  
 
Side population (SP) isolation. 
Briefly, 106 cells were trysinized and resuspended in 500 μL PBS containing 1% FBS 
previously to addition of Hoechst 33342 (5 μg/mL) (Fluka, Sigma-Aldrich Co., MO, 
USA; cat. # 14533), and 10 μmol/mL Fumitremorgin C (FTC) (Sigma-Aldrich Co., 
MO, USA; cat. # F9054) in the case of control tubes. Incubation was done in an orbital 
shacker at 37ºC for 90 min protected from light. At the end of the incubation, samples 
were centrifuged, washed twice with chilled PBS and filtered through a 40-μm nylon 
mesh previously to fluorescence-activated cell sorting (FACS) in a FACS Aria SORP 
cytometre (BD Biosciences, CA, USA). Sorted SP and non-SP fractions were collected 
in 96-well plates. 
 
Orthotopic xenograft model. 
Typically, 6-week-old virgin nu/nu female mice (n=6) were anesthetized by an 
intraperitoneal (i.p.) injection of 0.3 mL ketamine/xylacine and 17β-oestradiol pellets 
(Innovative Research of America, FL, USA; cat. # NE-121) were implanted on the 
lateral side of their necks. Three days after pellet implantation, 200 SP or non-SP MCF-
7 cells were resuspended in RPMI/Matrigel 1:1 and injected immediately after cell 
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sorting in the fat pad of the fourth mammary gland using a 27-gauge needle. Tumoral 
burden was estimated twice a week by palpation and tumour diameters were measured 
with calipers. Tumour volume was evaluated according to the equation: Volume = 
(Dxd2)/2, where ‘D’ is the major diameter of the tumour and ‘d’ the minor diameter. 
Experiments were performed in accordance with the European Communities Council, 
directives 86/609/EEC and 2007/526/CE. 
 
Statistical analysis. 
The data shown are the means ± standard deviation (SD) of at least three independent 
experiments. Statistical comparisons for significance between cells with different 
treatments were performed using the Student’s t test. Significance is represented as *, P 
< 0.05; **, P <0.01; ***, P < 0.001.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
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RESULTS 
In the later years, increasing evidences of significant antineoplastic effects of PPARγ 
agonists in different cancer cell types have been reported (Grommes et al., 2004), 
placing these compounds as potential therapeutic agents for the treatment of this 
disease.  Especially relevant is their antiproliferative and proapoptotic effect on breast 
cancer tumorigenesis, as it has been stated by several authors (Bonofiglio et al., 2006; 
Kim et al., 2006) and by previous work of our laboratory (Pignatelli et al., 2003; 
Pignatelli et al., 2001; Pignatelli et al., 2005). However, the mechanism by which 
PPARγ ligands exert their antineoplastic activity has not been yet fully elucidated. In 
this work we have further examined the mechanisms underlying the antitumorigenic 
effects of PPARγ ligands in breast carcinoma.  
 
1.- PPARγ LIGANDS INHIBIT GROWTH OF HUMAN BREAST CANCER 
CELL LINES. 
In this work, we first have further established the role of different PPARγ ligands on 
breast cancer cell proliferation, viability and apoptosis. With this aim, we have studied 
the effects caused by the natural PPARγ ligand 15-deoxi-Δ12,14-Prostaglandin J2 (15d-
PGJ2) and by the synthetic agonists rosiglitazone (RSG) and pioglitazone (PGZ), since 
these compounds have been reported to potently activate PPARγ.  
1.1.- PPARγ agonists significantly reduce viability of breast cancer cells. 
To evaluate the effect on cell growth of PPARγ ligands we performed studies on 
viability of the human breast cancer cell lines SKBR3, MCF-7, T47D and MDA-MB-
231 upon treatment with these compounds. Subconfluent cultures of these cell lines 
were treated with 10 μM 15d-PGJ2, 30 μM rosiglitazone or 10 μM pioglitazone for 24 
hours and cell viability was determined through colorimetric assessment of conversion 
of yellow 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) to 
purple formazan by viable cells. As it is shown in Figure 1, the three compounds cause 
a significant decrease in cell viability, with 15d-PGJ2 being responsible for the most 
dramatic effect, achieving a reduction of approximately 70% in cell viability 
independently of the cell line studied. Treatment with rosiglitazone and pioglitazone 
also leads to a decrease in viable cells, although the intensity of this effect at 24 hours is 
much lower than that of 15d-PGJ2. 
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1.2.- Treatment of breast cancer cells with PPARγ ligands leads to a significant 
reduction in cell proliferation. 
To better characterize the inhibition of growth following treatment with 15d-PGJ2, 
rosiglitazone or pioglitazone, we next analyzed whether the observed effect on viability 
was a result of impaired cell proliferation. With this purpose, incorporation of 
radiolabelled [3H]thymidine or of its non-radiactive analogue 5-Bromo-2-deoxy-uridine 
(BrdU) in exponentially growing cultures of four different human breast cancer cell 
lines treated or not with PPARγ agonists was assessed in order to quantitatively measure 
cell proliferation. The results from incorporation of radioactive thymidine (Fig. 2A) and 
BrdU (Fig. 2B), indicate that 15d-PGJ2, rosiglitazone and pioglitazone notably decrease 
cell proliferation in all the cell lines tested. In agreement with the results obtained on the 
evaluation of cell viability after treatment with PPARγ ligands, 15d-PGJ2 is the 
compound that exerts the most potent effects on cell proliferation, being even almost 
capable of completely blocking proliferation in the highly proliferative SKBR3 cell line 
after 24 hours of treatment. 
Figure 1. Effect on cell viability of PPARγ ligands on human breast cancer cell lines.  
Cells were incubated in the presence or absence of 15d-PGJ2 (10 μM), rosiglitazone (30 μM) or 
pioglitazone (10 μM) for 24 hours, as commented in Materials and Methods. Cell viability was 
determined by MTT assay. Results show the means ± SD (standard deviation) of 5 independent 
experiments with 5 replicates each. *, P < 0.05; **, P < 0.01; *** P < 0.001. 
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1.2.- Inhibition of growth in breast cancer cells upon treatment with PPARγ 
ligands is accompanied by increased apoptosis. 
Observation of the capacity of 15d-PGJ2, rosiglitazone and pioglitazone to cause cell 
death in breast cancer cells raised the possibility of these compounds acting as inducers 
of apoptosis. To test this hypothesis, we performed studies of flow cytometry to 
evaluate the presence of phosphatidylserine in the outer layer of the cytoplasmic 
membrane. Exposure of phosphatidylserine at the cell surface is a characteristic trait of 
the apoptotic process that can be detected through staining of the cells with annexin V-
FITC, a protein coupled to fluorescein capable of binding to phosphatidylserine. This 
method, in combination with the detection of the cells which are not stained by the dye 
propidium iodide (PI) that enters only death cells, is a suitable approach to assess 
induction of apoptosis in a cell culture. 
 
MCF-7 cells were seeded on 60 mm-diameter culture dishes and allowed to grow for 24 
hours before shifting medium to RPMI supplemented with 5% charcoal-stripped PBS. 
After 24 hours growing in these conditions, cells were treated with 10 μM 15d-PGJ2, 30 
μM rosiglitazone or 10 μM pioglitazone and both floating and adhered cells were 
collected for staining with Annexin V-FITC and PI using the human Annexin V-FITC 
Figure 2. Effect of PPARγ ligands on proliferation of human breast cancer cell lines. 
(A) Measurement of the incorporation of radiactive thymidine in SKBR3, MCF-7 and T47D cells 
treated during 24 hours in the presence of 10 μM 15d-PGJ2 or 30 μM rosiglitazone. Results 
correspond to 6 independent experiments with 8 replicates each. (B) Incorporation of BrdU in cells 
treated as in (A). The graphic represents the means ± SD of three independent experiments. **, P < 
0.01; *** P < 0.001. 
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kit (Bender MedSystems, Vienna, Austria), according to manufaturer’s guidelines.  
Treatment with 15d-PGJ2 for 24 hours was shown to be capable of significantly 
increasing the number of apoptotic cells (21%) in comparison with non-treated cultures 
(6%) (Fig. 3), whereas rosiglitazone and pioglitazone exhibit a milder effect (10 and 
8%, respectively).    
 
 
1.3.- Assessment of antineoplastic capacity of TDZDs in human breast cancer cells.  
Based on the observation of the potent antineoplastic effects of several PPARγ ligands, 
we sought to identify new potential therapeutic agents that exert similar effects in 
human breast carcinoma. Since compounds of the family of the thiadiazolidinones 
(TDZDs) show structure similarity with the TZDs group of PPARγ ligands that includes 
rosiglitazone and pioglitazone, and considering that TDZDs action has been reported to 
be mediated by PPARγ (Luna-Medina et al., 2005), we evaluated the effects of TDZDs 
on cell growth. 
 
1.4.- Effect of TDZD compounds on proliferation of human breast cancer cells. 
First of all, we assessed the effect exerted by the members of the TDZDs family known 
as NP00111, NP01138, NP031112, NP031115, NP031122, and TDZD-8 on 
proliferation of breast cancer SKBR3, MCF-7 and T47D cells. With this purpose, cells 
Figure 3. Analysis of induction of apoptosis by PPARγ agonists. 
MCF-7 cells were treated with 10 μM 15d-PGJ2, 30 μM rosiglitazone or 10 μM pioglitazone, 
afterwards the number of apoptotic cells was determined by Annexin V-FITC staining and FACS 
analysis. The graph represents the percentage of apoptotic cells in the cultures. *, P < 0.05; **, P < 
0.01. 
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growing exponentially in 96-well culture plates were cultured for 24 hours in RPMI 
supplemented with 5% stripped FBS before addition of the different compounds at a 
final concentration of 10 μM. After 24 hours, 0.5 mCi radiolabelled [3H]thymidine was 
added per well and incubation proceeded for another 24 hours. [3H]radioactivity 
measurements obtained after harvesting are represented in Figure 4. As it can be 
observed, all compounds cause a decrease in cell proliferation, although the most 
notable effect is that exerted by TDZD-8 and NP031122, that provoke a reduction in 
proliferation of approximately 70% in MCF-7 cells when compared to control cells.  
 
 
1.5.- TDZD-8 induces activation of a PPRE reporte gene together with reduction of 
cell viability and proliferation.  
Since other members of the TDZD family have been shown to be capable of activating 
PPARγ, we first studied the ability of TDZD-8 to induce activation of a PPRE reporter 
gene. To this end, we performed transient transfections in MCF-7 and T47D cells of the 
reporter plasmid pPPRE-tk-luc, containing three PPARγ consensus binding sites. As 
shown in Figure 5, TDZD-8 is capable of inducing the expression of the reporter 
construct, suggesting that this compound efficiently activates PPARγ.  
Figure 4. Effect of TDZDs  on proliferation of human breast cancer cell lines. 
SKBR3, MCF-7 and T47D cells were treated during 24 hours with the specified TDZDs at a 
concentration of 10 μM. After addition of 0.5 μCi of 3H-thymidine cells were harvested and 
incorporation of radiactive timidine was measured. Results are representative of 5 independent 
experiments with 8 duplicates each. *, P < 0.05; **, P < 0.01; *** P < 0.001. 
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We next evaluated the effects of TDZD-8 on breast cancer cell viability and 
proliferation. Regarding cell viability, transformation of yellow MTT to blue formazan 
by viable cells was measured in cultures of SKBR3, MCF-7, T47D and MDA-MB-231 
cells treated or not with TDZD-8 at a concentration of 10 or 20 μM. Figure 6 shows the 
decrease in cell viability caused by treatment with TDZD-8. This reduction is 
significant in all the cell lines tested, although it is even more dramatic in the case of 
SKBR3 cell line, where viable cells after 24 hours of treatment are reduced to less than 
20% of the original population.  
 
Effects on proliferation were analyzed in MCF-7 and SKBR-3 cells by monitoring 
BrdU incorporation after 24 hours of treatment with growing concentrations of TDZD-
8.  As it can be observed in Figure 7, TDZD-8 causes a decrease in cell proliferation in 
both cell lines, although in line with the results obtained in cell viability, the effect is 
more pronounced in the SKBR3 cell line. 
Figure 5. Activation of a PPRE reporter gene by 15d-PGJ2 and TDZD-8. 
MCF-7 cells were transfected with 0.2 μg of the PPRE-tk-luc reporter plasmid and harvested after 
24 hours of treatment with growing concentrations of 15d-PGJ2 or TDZD-8. Luciferase activity of 
cell lysates was determined. Data are expressed relative to the basal values and represent the means 
± SD luciferase activity determined in triplicate in three independent experiments. *, P < 0.05. 
 
73 
 
 
  
 
 
 
Figure 6. Viability of cells treated with TDZD-8. 
Cell viability assayed in four different human breast cancer cell lines following 24 hours of 
treatment with growing concentrations of  TDZD-8. Measurements indicate the means values ± SD 
of four independent MTT assays with 6 replicates each. *, P < 0.05; **, P < 0.01; *** P < 0.001. 
Figure 7. Effect of TDZD-8 on cell proliferation. 
Measurement of BrdU incorporation after 16 hours of treatment with growing concentrations of 
TDZD-8. Represented results correspond to means values ± SD of three independent experiments. 
*, P < 0.05; **, P < 0.01; *** P < 0.001. 
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1.6.- NP031122 reduces MCF-7 transformation capacity. 
To further assess the efficacy of NP031122, we performed colony-forming assays in 
soft agar to evaluate the clonogenicity of MCF-7 cells treated or not with NP031122. 
The ability of cells to exhibit anchorage independent growth and thus grow in a soft 
agar matrix, is a measure of cell transformation. We seeded MCF-7 cells in soft agar 
and 24 hours after seeding started to treat the cells with NRG1, that stimulates growth, 
NP031122 or a combination of both compounds. As it can be observed in Figure 8, 
MCF-7 control cells which had not been treated exhibit the ability to grow embedded in 
soft agar and originate numerous colonies. The number of colonies was increased upon 
treatment with NRG1 but decreases in presence of NP031122. When cells were treated 
at the same time with both NRG1 and NP031122, this TDZD reversed the proliferative 
 
  
Figure 8. Effect of NP031122 on clonogenicity of MCF-7 cells. 
Twenty hours after seeding in soft agar, cell were treated with NRG1 to promote growth in the 
presence or absence of NP031122 (10 μM). After 20 days in culture with periodic feeding and 
addition of the mentioned treatments, representative images of the resulting colonies were taken. As 
shown in the images, NP031122 causes a decrease in the number of colonies in comparison to both 
untreated cultures or cultures treated with NRG1.  Scale bar, 0.5 cm. 
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stimulus due to NRG1 and the number of resulting colonies was even lower to that in 
control non-treated cells. These results, similar to those exhibited by 15d-PGJ2 in the 
same cell type (Pignatelli et al., 2001), indicate that NP031122 can induce a notable 
decrease in cell growth and abrogate the transforming effects of NRG1 on MCF-7 cell 
line, reinforcing its potential as therapeutic agent. 
 
Although further study is needed, these results suggest a potential important role of 
TDZD-8 and NP031122 as therapeutic agents for human breast carcinoma. 
 
2.- 15d-PGJ2 BLOCKS PROLIFERATION INDUCED BY ACTIVATION OF 
ErbB RECEPTORS BY MEANS OF INCREASED PHOSPHATASE ACTIVITY. 
Previous studies from our laboratory indicate that an important part of the citostatic 
effects of the PPARγ ligand 15d-PGJ2 in breast cancer cells are due to its ability to 
revert the phosphorylation of ErbB2 and ErbB3 induced by NRG1 and NRG2 
(Pignatelli et al., 2001). We have further shown that preincubation of the cells with 
sodium orthovanadate (OVa4Na3), an inhibitor of protein tyrosine-phosphatases, impairs 
this reversion, suggesting that 15d-PGJ2 promotes dephosphorylation of ErbBs through 
a mechanism in which a phosphatase (or group of them) could be the main effector. 
Based on this data, we focused on the identification of this phosphatase. 
 
2.1.-  15d-PGJ2 does not alter the expression of SHP-1, SHP-2 and BDP1 
phosphatases. 
We initially analyzed three phosphatases, SHP-1, SHP-2 and BDP1, since they have 
been previously implicated in ErbB signalling pathways, as commented in the 
Introduction.  First of all, we analyzed the expression levels of these phosphatases over 
time in MCF-7 cells upon 15d-PGJ2 treatment to test if 15d-PGJ2 was upregulating their 
expression. As it is shown in Figure 9A no change in protein content of any of the 
phosphatases was observed. The maintenance of expression levels of all three 
phosphatases was corroborated by quantitative-PCR analysis, that showed no variation 
in messenger RNA (mRNA) transcription in response to treatment of MCF-7 cells with 
15d-PGJ2 (Fig. 9B). However, a transient shift in the electrophoretic mobility of SHP-1 
appeared 12 hours after addition of  15d-PGJ2.  
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2.2.- 15d-PGJ2 causes redistribution and membrane localization of SHP-1. 
We also studied the cellular localization of SHP-1, SHP-2 and BDP1 upon treatment 
with 15d-PGJ2. MCF-7 cells were treated with 15d-PGJ2 for 24 hours and fixed in 
methanol -20ºC. Immunofluorescence staining with the corresponding antibodies 
revealed a redistribution of SHP-1 phosphatase in response to treatment with 15d-PGJ2. 
In non-treated cells, SHP-1 exhibits a perinuclear localization, whereas in treated cells 
SHP-1 is located at the membrane and the nucleus (Figure 10). Membrane localization 
of ErbBs reinforces the possibility of a direct interaction with ErbB receptors.  
 
Figure 9. Changes in the expression levels of protein and mRNA of protein tyrosine 
phosphatases SHP-1, SHP-2 and BDP-1.  
(A) Western-blot analysis of protein expression of SHP-1, SHP-2 and BDP-1 phosphatases. No 
changes in protein content were detected upon treatment with 10 μM 15d-PGJ2. Content in α-
tubulin protein is presented as loading control. (B) Representation of the transcription levels of 
mRNA corresponding to the mentioned phosphatases upon treatment with 10 μM 15d-PGJ2 over 
time as determined by quantitative-PCR. *, P < 0.05; **, P < 0.01; *** P < 0.001. 
Figure 10. Redistribution 
of SHP-1 in response to 
15d-PGJ2 treatment.  
Representative images 
showing localization of 
SHP-1 in both basal (upper 
panels) and 15d-PGJ2–
treated cells (lower panels). 
Addition of 15d-PGJ2 
causes SHP-1 translocation 
from a perinuclear 
distribution to  membrane  
localization. Scale bar, 20 
μM.
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2.3.- 15d-PGJ2 induces SHP-1 phosphatase activation via its phosphorylation. 
Changes in electrophoretic mobility as the ones observed for SHP-1 in the western-blot 
assay are generally associated to post-transductional protein modifications such as 
phosphorylation, ubiquitination or sumoylation. With the purpose to verify if this 
alteration was caused by one of these modifications, MCF-7 cells were treated with 
15d-PGJ2 at different times and immunoprecipitation of SHP-1 within the 
corresponding lysates was performed. Then, the phosphorylation state of 
immunoprecipitated SHP-1 was analyzed. As it is shown in Figure 11A, SHP-1 
phosphorylation transiently increases after 12 hours of 15d-PGJ2 treatment; that is, at 
the same time than the mobility shift is observed. This observation indicates that the 
15d-PGJ2-induced shift is probably due to the phosphorylation of SHP-1. 
 
Interestingly, SHP-1 has been described to become active upon phosphorylation in its 
C-terminal tail (Frank et al., 2004; Uchida et al., 1994). This is an on/off mechanism 
that facilitates to change the activation state of the phosphatase rapidly and precisely. 
This fact lead us to analyze whether the modification of SHP-1 phosphorylation state 
implicated a concomitant change in its phosphatase activity, as this could explain the 
dephosphorylation observed in ErbBs upon 15d-PGJ2 addition. Cell lysates were 
obtained from MCF-7 cells exposed to 15d-PGJ2 during times varying from 0 to 24 
hours. After measuring protein concentration using the Bradford system, equal amounts 
Figure 11. SHP-1 phosphorylation and activity are transiently increased upon treatment with 
15d-PGJ2. 
(A) MCF-7 cells were treated during different time with 15d-PGJ2 and SHP-1 phosphatase was 
immunoprecipiated from the cell lysate. Phosphorylation of immunoprecipitated SHP-1 was 
determined by western-blot. Transient phosphorylation of SHP-1 is observed 12 hours after 
treatment with 15d-PGJ2. (B) SHP-1 phosphotyrosine phosphatase activity was assayed in the 
immunoprecipitates. Colorimetric measurements of activity are expressed in fold increase over 
basal levels. Values represent the media ± SD of three independent experiments. *, P < 0.05; **, P < 
0.01. 
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of proteins were subjected to SHP-1 immunoprecipitation. Measurements of tyrosine 
phosphatase activity of the immunoprecipitated SHP-1 phosphatase were perfomed 
using the Universal Tyrosine Phosphatase assay kit.  The results shown in Figure 11B 
revealed an increase on SHP-1 phosphotyrosine phosphatase activity 12 hours after the 
addition of 15d-PGJ2 to the culture medium, the same time than the mobility shift 
caused by phosphorylation of SHP-1 becomes evident. Thus, 12 hours after its addition, 
15d-PGJ2 induces a transient increase on SHP-1 phosphotyrosine phosphatase activity.  
 
2.4.- Knock-down of SHP-1 expression prevents 15d-PGJ2-induced ErbB2 
dephosphorylation. 
In order to assess the implication of SHP-1 in ErbB2 phosphorylation, we carried out 
transitory transfections of MCF-7 cells with an interference RNA (iRNA) against this 
phosphatase. As shown in Figure 12 iRNA is efficiently incorporated by most of the 
cells and interference of SHP-1 is successfully achieved, obtaining a significant 
reduction in the amount of phosphatase present within the cell.  
 
Figure 12. iRNA significantly reduces SHP-1 protein content within the cell. 
(A) Transfection of MCF-7 with a fluorescent iRNA (siGLO) to assess transfection efficiency. As 
shown in the photograph, the majority of the cells have successfully incorporated the iRNA 24 
hours after transfection. iRNA remained in the cells even 72 hours post-transfection. Scale bar, 20 
μM. (B) Representative western-blot and its quantification showing SHP-1 protein content in basal 
cells and in cells transfected with a non-targeting iRNA (Mock) or an iRNA against SHP-1 (iRNA). 
The image is representative for 3 independent experiments performed 24 and 48 hours after 
transfection. 
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Once evaluated the efficiency of transfection and that the iRNA against SHP-1 
remained within the cells at long experimental times such as 72 hours, subconfluent 
MCF-7 cells were then transfected with iRNA and grown during 24 hours in regular 
medium to allow recovery of the cells and interference of SHP-1. Then, cells were 
treated with 15d-PGJ2 for 12 hours and ErbB2 phosphorylation was stimulated 
afterwards by addition of NRG1 during 5 min. Analysis of ErbB2 phosphorylation state 
in immunoprecipitates of basal and SHP-1-interfered cells submitted or not to 
preincubation with NRG1 and/or 15d-PGJ2 (Fig. 13) reveals an increase in ErbB2 
phosphorylation when the expression levels of SHP-1 are decreased. Similarly, 
depletion of SHP-1 causes 15d-PGJ2-induced ErbB2 dephosphorylation to be milder 
than when SHP-1 is present.  
 
Altogether, these results suggest that activation of SHP-1 by 15d-PGJ2 would be 
responsible, at least in part, for the observed dephosphorylation effect of this 
prostaglandin on ErbB2 receptor. 
 
 
 
Figure 13. Effect of SHP-1 knock-down in 15d-PGJ2-induced ErbB2 dephosphorylation. 
MCF-7 cells were allowed to grow in regular medium  (lanes 1-4), transfected with a non-targeting 
iRNA (lane 5) or with an iRNA against SHP-1 phosphatase (lanes 6-9).  Twenty four hours post-
transfection, cells were treated with 10 μM 15d-PGJ2 (lanes 2, 4, 7 and 9) for 12 hours before 
stimulation of ErbB2 phosphorylation by addition of NRG1 (lane 3, 4, 8, 9) during 5 min. Then, 
cells were harvested and ErbB2 was immunoprecipitated. Image shows a representative western-
blot of the phosphorylation levels of ErbB2. An increase in ErbB2 phosphorylation is observed in 
NRG1-treated cells when the expression levels of SHP-1 are decreased (lane 8) in comparison to 
normal SHP-1 levels (lane 3). Moreover, the reversion of this phosphorylation in cells treated with 
15d-PGJ2 and NRG1 is lower in the SHP-1 knock-out (lane 9) than in presence of SHP-1 (lanes 4). 
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3.- 15d-PGJ2 INDUCES MITOTIC ARREST AS A RESULT OF 
MICROTUBULE DISRUPTION VIA TUBULIN BINDING. 
Previous studies performed in our laboratory on the induction of apoptosis in breast 
cancer cells by 15d-PGJ2 indicated that treatment with this prostaglandin promoted 
severe changes in the morphology of the mitochondria. Under basal conditions, 
mitochondria show an elongated shape with a form similar to that of a stick. However, 
shortly after addition of 15d-PGJ2 mitochondria become smaller and rounder, and their 
localization becomes mainly perinuclear. As it is well-known that the characteristic 
shape of mitochondria is due to its association to microtubules (Ball and Singer, 1982), 
we decided to analyze whether 15d-PGJ2 was responsible for inducing a disruption in 
microtubule architecture.  
 
First, we wanted to confirm the effects of 15d-PGJ2 on mitochondrial morphology. To 
this end, MCF-7 cells growing in glass coverslips in 24-well culture plates were treated 
with for 24 hours after which 20 nM Mitotracker Red CMXRos (Molecular Probes, 
Leiden, The Netherlands) was added for 45 min. As it is shown in Figure 14, confocal 
microscopy reveals morphological alterations in mitochondria, that acquire circular 
shape following treatment.  
 
 
Figure 14. 15d-PGJ2 induces alterations in mitochondrial morphology. 
Images show mitochondrial distribution and morphology in control cells and in cells treated for 24 
hours with 10 μM 15d-PGJ2. Scale bar, 20 μM. 
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Addition of 15d-PGJ2 also originated morphological changes in the microtubule 
network. Microtubules (MT) are intracellular, filamentous, polymeric structures 
composed of two structurally similar protein subunits, namely, α- and β-tubulin 
(molecular weight, 50 kDa each). They constitute the principal component of the 
cytoskeleton network of eukaryotic cells and have been shown to be deeply involved in 
cell division, cytokinesis, maintenance of cell morphology, and signal transduction 
(Jordan and Wilson, 2004). During mitosis, microtubules undergo rapid polymerization 
and depolymerization to enable movement of chromosomes. As cell division 
approaches metaphase, microtubules are disrupted and form a spindle surrounding the 
centrosome, thereby facilitating chromosomal alignment on the metaphase plate. In this 
process, tubulin subunits freely exchange on the microtubules. If such free exchange of 
tubulin subunits is disrupted, the mitotic spindle is compromised and the cell cannot 
divide. Thus, drugs such as nocodazole that affect microtubule organization by binding 
to tubulin and preventing its incorporation into growing microtubules impair cell 
division and constitute therefore an important class of antineoplastic compounds.  
 
3.1.- 15d-PGJ2 arrests the cell cycle at G2/M phase. 
Based on the commented mitochondrial alterations observed in response to treatment of 
MCF-7 cells with 15d-PGJ2, we reasoned that 15d-PGJ2 could be causing disruption of 
the microtubule network. It is well documented that MT inhibitors arrest cells in G2/M 
phase and induce therefore cell death. Thus, if 15d-PGJ2 provokes significant 
microtubule disorganization, a concomitant effect on cell cycle should be appreciated. 
 
To determine the effect of 15d-PGJ2 on cell cycle, exponentially growing MCF-7 cells 
were treated with 15d-PGJ2 for 24 hours and their cell cycle progression was followed 
by fluorescence activated cell sorting analysis. Figure 15 demonstrates that treatment 
with 15d-PGJ2 led to significant accumulation of cells in the G2/M compartment of the 
cell cycle, compared with non-treated control cells. On the contrary, the percentage of 
cells in the G2/M cell cycle state did not differ markedly between control and MCF-7 
cells treated with rosiglitazone. Nocodazole, a potent anti-microtubule agent capable of 
rapidly depolymerizing the MT network, was used as control. Nocodazole is known to 
cause microtubule disruption by binding to β-tubulin, impairing thus its incorporation in 
the microtubule.  
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Figure 15. Effects on cell cycle of treatment with 15d-PGJ2 and rosiglitazone.  
Effect of 15d-PGJ2 and rosiglitazone on cell cycle distribution of exponentially dividing MCF-7 
cells. Cells were exposed to 10 μM 15d-PGJ2, 30 μM rosiglitazone (RSG) or 1 μM nocodazole for 
24 hours and analyzed by FACS. Nocodazole was used as positive control of microtubule 
depolymerization The numbers in the table indicate the percentage ± SD of cells in each phase of 
the cell cycle. Data are representative of three independent experiments. *, P < 0.05; *** P < 0.001. 
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3.2.- 15d-PGJ2 disrupts the cytoskeleton network by depolymerizing microtubules. 
Once verified that 15d-PGJ2 promotes similar effects on cell cycle to those of MT 
inhibitors, causing arrest at G2/M phase, we had to confirm that 15d-PGJ2 was a real 
microtubule disruptor. To test this, we first examined whether 15d-PGJ2 could directly 
affect the organization of the MT network of MCF-7 cells in interphase. MCF-7 cells 
were treated with 15d-PGJ2, rosiglitazone, or nocodazole and the MT network was 
visualized by immunofluorescence after 12 hours of incubation. In control cells, the MT 
network exhibited normal arrangement with MT seen to traverse intricately throughout 
the cell and a normal compact rounded nucleus (Fig.16). In contrast, 15d-PGJ2 
treatment caused a dramatic disruption of the MCF-7 cytoskeleton, producing a diffuse 
MT network. These effects, which are similar to those exerted by nocodazole, were not 
observed after rosiglitazone treatment. The multiple-dot pericentrin pattern obtained is 
characteristic of certain breast cancer cell lines (Schneeweiss et al., 2003) and was 
corroborated by γ-tubulin staining. 
 
Figure 16. Disruption of microtubules in 15d-PGJ2-treated MCF-7 cells.  
Cells were treated for with 1 μM nocodazole, 10 μM 15d-PGJ2 or 30 μM rosiglitazone (RSG) and 
stained with anti-α-tubulin and anti-pericentrin. DNA was stained with DAPI. Scale bar, 10 μm.  
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To further demonstrate that 15d-PGJ2 could promote MT depolymerization in vivo, we 
assessed the fraction of free and polymerized α-tubulin in control and 15d-PGJ2-treated 
MCF-7 cells, by harvesting the cells in a MT-stabilizing buffer and performing 
differential sedimentation. The amount of polymerized α-tubulin in the pellet fraction 
was significantly decreased 12 hours after treatment with 15d-PGJ2, when compared 
with basal cultures (Fig. 17). In contrast, we could not observe any decrease in 
polymerized tubulin after treatment with rosiglitazone, in comparison with control cells. 
 
3.3.- Microtubule disorganization after 15d-PGJ2 treatment results in mitotic 
abnormalities. 
MT targeting agents arrest the cell cycle in early mitosis i.e. prometaphase/metaphase. 
Therefore, we investigated the effect of 15d-PGJ2 on MCF-7 cell division by examining 
mitotic figures in MCF-7 cells treated or not with 15d-PGJ2 for 24 hours, fixed and co-
stained with 4,6-diamidino-2-phenylindole (DAPI) and anti-α-tubulin and anti-
pericentrin antibodies to monitor DNA, mitotic spindle, and centrosomes, respectively. 
Cell morphology and percentage of cells at different stages of mitosis and cytokinesis 
were determined using confocal microscopy. Untreated cells rounded up at the 
beginning of mitosis and split into two symmetrical daughter cells as expected (Fig. 18).  
Figure 17. Assessment of the ratio soluble/polymerized  
(A) Polymerized tubulin (P) was differentially extracted from soluble (S) tubulin in control, 
rosiglitazone (RSG), and 15d-PGJ2-treated MCF-7 cell lysates prepared in a microtubule-stabilizing 
buffer. Soluble and polymerized tubulin fractions were then analyzed by blotting for α-tubulin. (B) 
Tubulin bands were quantified by densitometric analysis and expressed as a percentage of total 
tubulin levels. *, P < 0.05. 
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In contrast, although 15d-PGJ2-treated cells developed spindle-like structures (Fig. 19), 
the MT fibers generally lack the organization observed in control cells. Also, in the 
cultures treated with 15d-PGJ2, we could not detect any cell proceeding to either 
anaphase or telophase/cytokinesis and these cells displayed distinct signs of arrest in the 
metaphase stage of mitosis as the nuclear membrane has disappeared and the chromatin 
was condensed. The major changes, however, were the complete absence of anaphase 
and telophase cells and the large increase in the percentage of metaphase cells 
exhibiting metaphase plates with incomplete chromosome alignment, following 15d-
PGJ2 treatment. Cells with such characteristics were unable to undergo cytokinesis.  
Figure 18. Non-treated MCF-7 progression through the cell cycle.  
Shown are representative confocal images of MCF-7 cells mitotic progression. Control cells were 
fixed and stained with anti-α-tubulin and anti-pericentrin. DNA was stained with DAPI. Scale bar, 
10 μm.  
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Figure 20. Cell distribution in 
the different phases of the 
cell cycle. 
Frequency of mitotic stages in 
control and 15d-PGJ2-treated 
MCF-7 cells was quantified 
and expressed as a percentage 
of total cells. ***, P < 0.001. 
 
The stage of mitosis at which the block occurred was further determined by counting 
the number of cells at each stage of mitosis. As shown in Figure 20, in the 15d-PGJ2-
treated MCF-7 cells, the number of cells in anaphase and telophase/cytokinesis 
decreased to zero, indicating a block specifically at the transition from metaphase to 
anaphase. These results suggest that 15d-PGJ2 acts as a mitotic inhibitor, causing failure 
to form a stable metaphase plate, incapacity to progress through anaphase, and failure to 
complete cytokinesis. 
 
Figure 19. Treatment of MCF-7 cells with 15d-PGJ2 perturbs mitotic progression.  
Cells treated for 24 hours with 15d-PGJ2 were fixed and stained with anti-α-tubulin and anti-
pericentrin. DNA was stained with DAPI. Shown are representative confocal images of the mitotic 
progression of  15d-PGJ2-treated MCF-7 cells. Scale bar, 10 μm. 
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Time-lapse microscopy was utilized to characterize the fate of MCF-7 cells treated with 
15d-PGJ2 and rosiglitazone (Fig. 21 and Supplementary Videos 1-3). We have found 
that the majority of control non-treated cells undergo cell division within 80 to 90 min 
(Fig. 21 and Supplementary Video 1). Non-treated cells segregate chromosomes, 
proceed through anaphase, initiate furrow formation and elongate the midbodies. 
Eventually the cells segregate and flatten out. However, the majority of 15d-PGJ2-
treated cells took 3 hours or longer for a significant number of cells to proceed to 
metaphase. During that time, cells could go through the nuclear envelope breakdown 
but they were unable to form a stable metaphase plate with all the chromosomes aligned 
to it and eventually proceed to anaphase. The single prominent phenotype associated 
with 15d-PGJ2 treatment was failure to complete cytokinesis. After more than 7 hours in 
‘metaphase-like’ stage, cells shriveled and died (Fig. 21, Supplementary Video 2). 
 
Figure 21. Analysis of mitosis in live MCF-7 cells.  
Representative images from time-lapse analysis of live cells showing the different phases of mitosis. 
Time zero, shown in minutes, is the time point at which the nuclear envelope is broken down and 
chromatin condensation is evident, just at prophase onset. Cultures were incubated with 10 μM 15d-
PGJ2 or 30 μM rosiglitazone (RSG) and areas were subsequently followed by time-lapse 
microscopy. Cells treated with 15d-PGJ2 remained in metaphase for more than 8 hours afterward 
they die. In contrast, non-treated and rosiglitazone-treated cells escaped mitosis after ~ 1 hour. Scale 
bars, 50 (lower magnification) and 10 (higher magnification) μm. Time-lapse movies for the 
sequential images shown in this Figure can be found in the accompanying  CD. 
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When MCF-7 cells were treated with rosiglitazone, no significant differences in the 
process of mitosis were observed (Fig. 21 and Supplementary Video 3). Cells treated 
with rosiglitazone were able to complete mitosis within a period of time similar to the 
one observed for control non-treated cells. When taken together with the images shown 
in Figure 19, these results provide compelling evidence that treatment of MCF-7 cells 
with 15d-PGJ2 results in failure of cell division through arrested metaphase. 
 
3.4.- 15d-PGJ2 causes microtubule depolymerization through direct binding to 
tubulin. 
Because 15d-PGJ2 markedly disrupted the cellular MT network, we tested whether 15d-
PGJ2 could directly affect tubulin, the main component of this network. An in vitro 
biochemical tubulin polymerization assay was carried out to investigate the activity of 
15d-PGJ2 on MT function. Results presented in Figure 22 show that 15d-PGJ2 
significantly inhibited the polymerization of tubulin, similar to the effect elicited by 
nocodazole, a well-known MT destabilizer. On the contrary, the addition of paclitaxel, 
in agreement with previous reports, favours tubulin polymerization. In contrast, 
rosiglitazone was found to have a negligible effect upon the polymerization of tubulin in 
vitro, relative to the vehicle control (data not shown), in agreement with its lack of 
effect upon the cellular MT network. This again, distinguishes the mechanism of action 
of both PPARγ ligands and suggests that the effects of 15d-PGJ2 are independent of 
PPARγ activation. These data suggest that 15d-PGJ2 could bind directly to tubulin and 
thereby prevent its polymerization and identify tubulin as a molecular target of 15d-
PGJ2. 
 
The possibility that 15d-PGJ2 could directly bind to, both α- and β-tubulin in vivo was 
investigated by using a biotinylated 15d-PGJ2 derivative. To this end, we first analyzed 
the incorporation of biotinylated 15d-PGJ2 into α- and β-tubulin by Neutravidin-gel pull 
down followed by Western blot with anti-α-tubulin or anti-β-tubulin antibodies. Figure 
23 shows that α- and β-tubulin present in lysates from biotinylated 15d-PGJ2-treated 
MCF-7 cells were retained on Neutravidin beads, suggesting that 15d-PGJ2 is able to 
react with endogenous α- and β-tubulin in intact MCF-7 cells.  
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Figure 23. Binding of biotinilated 15d-PGJ2 to α- and β-tubulin in vivo.  
MCF-7 cells were incubated or not with biotinilated 15d-PGJ2 for 2 hours and cell lysates were 
subjected to pull-down assays with Neutravidin-gel beads. The presence of α- and β-tubulin was 
assessed by Western blot analysis with specific antibodies. 
Figure 22. Effect of 15d-PGJ2 on tubulin polymerization in vitro.  
Purified bovine brain tubulin was incubated in the presence of buffer (blank), 1 μM nocodazole, 10 
μM 15d-PGJ2, or 200 μM paclitaxel at 37ºC, and absorbance readings were recorded at 340 nm each 
30 seconds for 1 hour. Data are representative of two independent experiments performed in triplicate. 
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To further analyze the in vivo association between tubulin and 15d-PGJ2 in the living 
cell, we performed confocal microscopy analysis of MCF-7 cells treated or not with 
biotinylated 15d-PGJ2 for 2 hours and stained with anti-α- or anti-β-tubulin. As shown 
in Figure 24A, a biotinylated 15d-PGJ2 network, which colocalized with the 
endogenous tubulin network was clearly seen. This colocalization is also observed as 
the cell progresses into the cell cycle (Fig. 24B). These results further suggest a direct 
binding between 15d-PGJ2 and the MT network. 
 
The above results indicate that 15d-PGJ2 binds to both α- and β-tubulin. Therefore, we 
next analyzed untreated and 15d-PGJ2-treated microtubules samples by mass 
spectrometry (MS) to characterize the binding site(s) of 15d-PGJ2 within tubulin. We 
used a recently reported approach based on hybrid triple-quadrupole mass spectrometry 
to find the 15d-PGJ2-binding site(s) (Buey et al., 2007). We first made the 
characterization of 15d-PGJ2 molecule by off line mass spectrometric analysis, and an 
ion at m/z 317.4 Da, corresponding to the monoisotopic, protonated 15d-PGJ2 molecule, 
was observed (Fig. 25A). In order to find the main fragments corresponding to single or 
multiple cleavage sites within the 15d-PGJ2 molecule, an enhanced product ion 
experiment was performed (Fig. 25B).  
 
Figure 24. Binding of biotinilated 15d-PGJ2 to α- and β-tubulin in vivo.  
(A) Evaluation by confocal microscopy of binding of biotinylated 15d-PGJ2 to MCF-7 cells. MCF-7 
cells were untreated (upper panels) or treated with 15d-PGJ2 (lower panels) for 2 hours. Scale bar, 
10 μm. (B) Same staining as in B, showing colocalization of biotinylated 15d-PG2 in mitotic cells. 
Scale bar, 20 μm.  
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Figure 25.  Off line 
nanospray 
characterization of 15d-
PGJ2 by triple 
quadrupole MS.  
An ion at m/z 317.3 Da, 
corresponding to the 
monoisotopic, protonated 
15d-PGJ2 molecule, was 
observed (A). In order to 
find the main fragments 
corresponding to single or 
multiple cleavage sites 
within the 15d-PGJ2 
molecule, an enhanced 
product ion experiment was 
performed. The ion at m/z 
317.3 Da was isolated and 
fragmented (B). The most 
intense fragment ions were 
selected as potential 
markers for later precursor 
ion scanning experiments 
in order to find the best 
marker mass to select 
precursor ions for filtration 
of peptides that were 
tagged with 15d-PGJ2. The 
fragment ion at m/z 299.4 
Da was the signal of choice 
for precursor ion filtering 
experiments (C). The 
efficiency of precursor ion 
scanning experiments was 
lower when using other 
fragment ions present in 
the MS/MS spectrum from 
the 15d-PGJ2 molecule 
(black arrows) (C). 
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The most intense fragment ions were selected as potential markers for later precursor 
ion scanning experiments. The fragment ion at m/z 299.4 Da, out of the seven tested 
(145.2, 169.2, 183.2, 197.2, 215.4, 281.4, and 299.4), was the signal of choice for 
precursor ion filtering experiments (Fig. 20C). The efficiency of precursor ion scanning 
experiments was lower when using the other seven fragment ions present in the MS/MS 
spectrum from the 15d-PGJ2 molecule (Fig. 20C). Precursor ion scanning-MS 
chromatograms of trypsin-digested microtulules from untreated (Fig. 26, upper panel) 
or 15d-PGJ2-treated (Fig. 26, lower panel) samples were analyzed.  
 
Although no differential, intense chromatographic peaks were found, an exhaustive 
mass composition chromatographic analysis revealed six time positions (1-6 in Fig. 26) 
along the chromatograms corresponding to differential signals producing the 15d-PGJ2-
derived fragment ion at m/z 299.4 Da. These time positions marked the elution time for 
differential signals tagged with 15d-PGJ2 (Fig. 27), which were only present in the 15d-
PGJ2-treated sample, as indicated by the asterisks (Fig. 27). 
 
MS/MS-based peptide sequencing of differential masses 1, 2, and 4 (Fig. 28) 
demonstrated that these sequences (353-TAVCPGDIPPR-361, 300-NMMAACPGDPR-
308, and 219-LTTPTYGDLNHLVSATMSGVTTCPGLR-243, respectively) mapped 
into β-tubulin, while the sequences from differential masses 3 (312-YMACCPGLLYR-
320), and 5 (309-HGKYMACCPGLLYR-320; one missed cleavage at K311; not shown) 
corresponded to α-tubulin-derived peptides (Fig. 28). A comprehensive study of the 
Figure 26. MS analyses of 15d-PGJ2 binding to microtubules. 
Total ion chromatogram (TIC) of the precursor ion scanning of fragment at m/z 299.4 from control 
(upper panel) or 15d-PGJ2-treated (lower panel) microtubules samples, digested with trypsin. 
Arrows labelled as 1-4 indicate retention times corresponding to different peptide mass composition 
between control and 15d-PGJ2-treated microtubules samples. 
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fragmentation spectra from the parent ions corresponding to masses 1-5 revealed that in 
all cases the cysteine within the sequence was the 15d-PGJ2-binding residue 
(superscripted PG-cysteine in text and Fig. 28). For peptides 3 and 5, only one of the 
two cysteine residues was modified by 15d-PGJ2. Differential mass 6 corresponded to 
the unbound 15d-PGJ2 dimer, appearing later on the chromatogram due to the highly 
hydrophobic nature of the molecule. In conclusion, 15d-PGJ2 binds to tubulin through 
the formation of a covalent adduct with at least four cysteine residues, one in α- 
(cysteine 316) and three in β-tubulin (cysteine 241, 305 and 356).  
 
 
Figure 27. Analysis of differential mass composition. 
Labels 1-4 indicate the 15d-PGJ2-modified sequences. C means control-, and PG means 15d-PGJ2-
treated microtubules samples. Differential masses absent in the control mass spectrum are labelled 
as an (*). Peaks 5 and 6 correspond to differential chromatographic peaks. Peak 5 contains the 
peptide with sequence 309-HGKYMACCPGLLYR-320 (one missed cleavage at K311). Peak 6 
corresponds to the 15d-PGJ2 dimer. 
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These results were verified by Multiple Reaction Monitoring (MRM) experiments (Fig. 
29). Ions at m/z 644.4, 662.9, 726.4, and 989.9 (corresponding to differential masses 1, 
2, 3, and 4, respectively) were isolated and fragmented in untreated and 15d-PGJ2-
treated microtubules samples. As can be observed, only in the 15d-PGJ2-treated 
chromatogram, the four differential, intense chromatographic peaks were detected (Fig. 
29). 
 
Figure 28. Characterization of 15d-PGJ2 binding site by triple quadrupole MS.  
The figure displays the main fragmentation series (carboxy, y, and amino, b, series) for the doubly-
charged parent ions from peak 1-3 (A-C, respectively), and for the triply-charged parent ion from 
peak 4 (D). On each panel the corresponding peptide sequence is shown, as well as fragments 
containing the 15d-PGJ2 (superscripted PG). Numbers in boxes (including the filtering mass at m/z 
299.4 Da for the precursor ion scanning experiments) indicate masses resulting from fragmentation 
of the 15d-PGJ2 molecule. Water loss of some fragments are marked with an (*), and some 
secondary fragmentation series peptides (a series) are also indicated. 
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4.- PPARγ LIGANDS EFFICIENTLY REDUCE HUMAN BREAST CANCER 
STEM CELL POPULATION. 
To be considered an antitumorigenic drug, a compound must be capable of causing 
tumour shrinkage, an effect that is usually achieved by inhibiting tumour growth and 
promoting cell death processes such as apoptosis. However, the assumption of the 
cancer stem model has included an additional premise for a compound to be considered 
potently antitumorigenic: the compound must be capable of eradicating cancer stem 
cells. Otherwise, as these cells are able to reconstitute the whole tumour, tumour will 
relapse even in the case that only a single cancer stem cell survives therapy. Thus, cell 
death must not only be assessed in the bulk of the tumour but also in the subset of cells 
that constitute its stem cell population. 
 
Ligands for PPARγ have a potent antitumorigenic capacity, as this work and others 
prove. However, their effect on cancer stem cells has not been tested so far. In order to 
evaluate the antiproliferative and proapoptotic potential on human breast cancer stem 
cells, we have performed an in-depth study on the outcome of the treatment of these 
cells with different PPARγ ligands. 
 
 
Figure 29. MRM experiments with control and 15d-PGJ2-treated microtubules samples.  
MRM experiments from tryptic, 15d-PGJ2-modified peptides 1-4. The inset shows the MRM results 
for the corresponding control microtubules sample.  
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4.1.- Human breast cancer cell lines contain cancer stem cells. 
To this end, we first cultured human breast cancer cell lines SKBR3, MDA-MB-231, 
MCF-7 and T47D under non-adherent conditions in DMEM/HAM’S F12 medium 
supplemented with 20 ng/mL epidermal growth factor (EGF), 20 ng/mL basic fibroblast 
growth factor (bFGF), and B27 supplement. Under these conditions only cancer stem 
cells survive, whereas non-stem cells undergo a process of anoikis which results in 
death (Dontu et al., 2003). While cultured in this medium, cancer stem cells grow and 
divide, originating globular structures in the form of a condensed sphere which are 
commonly known as primary mammospheres and which are supposed to be enriched in 
progenitor cells. As Figure 30  reveals, all the cell lines tested contain cancer stem cells, 
as they are able to generate mammospheres. Spheres formed by MCF-7  and T47D cells 
are circular and condensed, whereas MDA-MB-231-derived spheres had a more 
irregular and less condensed morphology. SKBR3 showed a great ability to adhere to 
the culture dish, although cultured in ultra-low adherence-plates. 
 
To evaluate the mammosphere formation frequency of each cell line, 2,000 cels/mL 
were seeded onto low-adherence plates and the number of spheres originated was 
estimated (Fig. 31). Differences in the frequency of mammosphere formation were 
appreciated, with ~1% of the initial MCF-7 and T47D cells originating spheres and 
lower percentages (~0.5%) for SKBR3 and MDA-MB-231 cell lines. This observation 
suggests that cancer stem cells are present in a different proportion in each cell line. 
Figure 30. Cultures of breast cancer cell lines. 
Shown are representative images of SKBR3, MCF-7, T47D and MDA-MB-231 cell lines cultured 
under adherent conditions (upper panels) and under non-adherent conditions as mammospheres 
(lower panels). Scale bar, 25 μM.  
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4.2.- PPARγ ligands dramatically reduce primary mammosphere number and size. 
To directly assess the effect of PPARγ ligands in breast cancer stem cells without 
interferences from cells of the bulk of the tumour equal amounts of primary 
mammospheres originated from MCF-7 cells were treated along 12 days with 10 μM 
15d-PGJ2, 30 μM rosiglitazone and 10 μM pioglitazone respectively. As it can be 
observed in Figure 32, all PPARγ ligands tested caused a dramatic reduction in sphere 
number and size, with 15d-PGJ2 and rosiglitazone inducing complete dissociation of the 
sphere and death of the cells that were forming it. A similar but milder effect is 
observed upon pioglitazone treatment. 
 
Figure 32. Effect of PPARγ ligands on mammosphere growth. 
MCF-7-derived mammospheres were cultured for 12 days in presence or absence of 10 μM 15d-
PGJ2, 30 μM rosiglitazone (RSG) and 10 μM pioglitazone (PGZ).  Images show the decrease of 
both mammosphere number and size in response to the different treatments. Scale bar, 200 μM. 
 
Figure 31. Mammosphere forming-frequency in breast cancer cells. 
Two thousand viable cells from each cell line were seeded under non-adherent conditions, and the 
number of mammospheres formed after 5 days was counted. Results represent the mean ± SD of 
three independent experiments. 
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4.3.- Treatment with PPARγ ligands impairs mammosphere self-renewal. 
As commented above, antitumorigenic drugs must guarantee elimination of every 
cancer stem cell to avoid tumour relapse. One of the characteristics that defines cancer 
stem cells is their ability to self-renew, that is, to undergo asymmetric divisions that 
generate an identical daughter cell which is therefore a cancer stem cell, and a second 
more differentiated daughter cell that will form part of the bulk of the tumour. Thus, 
evaluation of self-renewal capacity after treatment with an antitumorigenic drug is 
fundamental to define its potential.  
 
The ability of cells that constitute a primary sphere to originate a secondary 
mammosphere after dissociation of the former is a trait of self-renewal capacity. We 
used this property to assess the self-renewal capacity of mammospheres after treatment 
with PPARγ ligands. Mammospheres derived from MCF-7 cells were grown during 5 
days in regular medium. Then, spheres were maintained in regular medium or treated 
with 15d-PGJ2, RSG or PGZ for 5 days (days 6-10). A decrease in mammosphere 
number and size proportionally similar to that stated in the previous section was 
observable after 5 days of treatment (day 10). Then, medium was shifted and treatment  
 
was added to half of the basal cultures, while treatment was maintained in half of the 
previously treated cultures and arrested in the other half. Spheres were allowed to grow 
for 5 additional days (day 10-15). Like this, we obtained cultures grown under basal 
conditions, cultures that had been treated only during the initial or the final period and 
cultures that had been treated during all the process. Figure 33 illustrates the results 
Figure 33. Assessment of self-renewal capacity. 
Self renewal capacity mammospheres derived from MCF-7 cells grown under basal conditions (1) 
or treated with 10 μM pioglitazone (3). In the case of (2), spheres were cultured under basal 
conditions for 5 days and treated with pioglitazone during the next 5 days. Conversely was done in 
(4), cells were treated during the first 5 days and not treated in the following 5 days. Growth factor 
supplementation was performed every 2.5 days. Scale bar, 250 μM.  
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obtained for spheres treated with PGZ. Images from cultures with 15d-PGJ2 and RSG 
are not presented as treatment with these agents causes such a dramatic effect that no 
viable cell is detected after 5 days of treatment with any of these drugs. As it can be 
observed in the images, treatment with PGZ causes a decrease in mammosphere number 
and size which is dependent on the exposure time, and, more importantly, spheres 
treated with PGZ only during the first period are not able to self-renew and originate de 
novo more spheres than the ones which are already present. 
 
4.4.- CD44+/CD24-/low expression profile is a marker for basal origin but not 
‘stemness’. 
Because recent studies have performed a parallel identification of human breast cancer 
stem cells and concluded that these cells can be identified by analysis of the membrane 
antigens CD44 and CD24, we analyzed the presence in our cultures of cells with the 
CD44+/CD24-/low expression profile that had been proposed as marker of ‘stemness’. 
Adherent cultures of SKBR3, MDA-MB-231, MCF-7 and T47D cells were stained with 
fluorescent antibodies recognizing human CD44 and CD24 and phenotype distribution 
was analyzed by flow cytometry, as it is shown in Figure 34.  
 
Figure 34. Flow 
cytometry analysis of 
CD44 and CD24 
expression in adherent 
human breast cancer 
cell lines.  
Detection of CD44 and 
CD24 membrane antigens 
in MCF-7, SKBR3, T47D 
and MDA-MB-231 cell 
lines. Representative 
graphs indicative of the 
distribution of both 
markers in 4 independent 
experiments are shown.  
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As it can be observed in the table showing the phenotype distribution (Figure 35, upper 
panel), cells from luminal origin (MCF-7, SKBR3 and T47D) are depleted of 
CD44+/CD24-/low cells, whereas cell lines from basal origin (MDA-MB-231) are almost 
100% CD44+/CD24-/low. These results, together with the fact that mammosphere-
forming assays had already shown that MCF-7, SKBR3 and T47D cell lines contain 
cancer stem cells, lead us to think that CD44+/CD24-/low phenotype identifies cells from 
basal origin, instead of cells with stem properties.  
 
In addition, similar studies were performed in primary mammospheres derived from 
each of the previously mentioned cell lines. It is widely accepted that mammospheres 
are enriched in progenitor cells, and consequently, if breast cancer stem cells are 
represented by the CD44+/CD24-/low phenotype, the proportion of cells showing this 
phenotype should be higher in mammospheres in comparison with adherent cultures. 
However, when analysis of CD44 and CD24 expression is performed in 
mammospheres, exactly similar phenotype distribution than in normal cultures is 
obtained (Figure 35, lower panel). This findings corroborate our findings that 
CD44+/CD24-/low phenotype is not a marker for human breast cancer stem cells but for 
basal origin.  
 
 
Figure 35. Frequency of CD44+/CD24-/low  population in adherent cultures and mammospheres. 
Percentages of the resulting phenotypes after screening for CD44 and CD24 expression. Upper table 
indicates the percentages observed in adherent cultures whereas lower table refers to cultures of 
mammospheres. Shown are means of 3 independent experiments ± SD.  
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4.5.- Identification of the Side population in MCF-7 cell line.  
The lack of markers to directly identify breast cancer stem cells within a cell population 
limits the studies of the effects of potential therapeutic agents on cancer stem cells to 
indirect methods such as the previously commented mammosphere culture. 
Nonetheless, some authors consider cells in the side population (SP) as a model for 
cancer stem cells, since some studies have reported higher colony-formation capacity 
and greater tumorigenicity in vivo for SP cells than for non-SP cells (Engelmann et al., 
2008; Zhou et al., 2007).   
 
In order to evaluate the effect of PPARγ ligands on the SP we first performed flow 
cytometry studies to detect this population. The SP is a subset of cells with the property 
to differentially efflux the vital dye Hoechst 33342, which exits the cell through the 
drug resistance transporter ABCG2. When blue and red fluorescence of Hoechst 33342 
are plotted one against each other, SP appears as a tail-like structure. We used this 
approach to identify the SP in MCF-7 cells (Fig. 36). To ensure that this population 
corresponded to SP cells, a control treated with the specific inhibitor of ABCG2 
fumitremorgin C (FTC) was included.  
 
 
Figure 36. Detection by flow cytometry of Side Population in MCF-7 cells.  
MCF-7 cells were stained with 5 μg/mL Hoechst 33342. SP cells differentially efflux the dye 
through their ABCG2 transporter and appear as a tail-like structure when Hoechst-red signal is 
displayed vs. Hoechst-blue signal. Control samples were added 10 μmol/mL of the ABCG2 
inhibitor Fumitremorgin C (FTC).  
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4.6.- Side population remains unaltered upon treatment with PPARγ ligands. 
Once identified the SP in MCF-7 cells we sought to evaluate alterations in this 
population following treatment with PPARγ ligands. MCF-7 cells were shifted to RPMI 
medium containing 5% stripped FBS and allowed to grow for 24 hours before addition 
of 10 μM 15d-PGJ2 or 30 μM rosiglitazone. After 24 hours exposed to treatment, cells 
were trypsinized and incubated with 5 μg/mL Hoechst 33342 during 90 min at 37ºC 
previously to analysis in a MoFlo cytometre. The percentage of cells in the SP relative 
to the total population was determined for both basal and treated cells. As shown in 
Figure 37, the proportion of cells comprising the SP subpopulation remains constant 
upon treatment with 15d-PGJ2 and rosiglitazone.  
 
4.7.- SP and non-SP cells show similar colony-formation efficiency in vitro and 
tumorigenicity in vivo. 
To verify that SP fraction is enriched in cells with stem properties, we isolated the SP in 
MCF-7 cells as previously described. Isolation was performed in a FACS Aria SORP 
cytometre. Cells within the SP fraction were sorted to a low-adherent multi-well plate at 
the same time that a subset of cells showing a distribution distant from the SP region 
were isolated to be used as control non-SP cells. 
 
Figure 37. Determination of changes in SP upon treatment with PPARγ ligands. 
MCF-7 cells cultured in basal conditions or treated for 24 hours with 10 μM 15d-PGJ2 or 30 μM 
rosiglitazone (RSG) were subjected to flow cytometry analysis of their SP. Results indicate non-
significant variability of the percentage of cells that comprise the SP in response to the different 
treatments.  
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Immediately after cell sorting the cells were divided in two groups. With one group 
colony-formation efficiency was evaluated. Both SP and non-SP cells were plated 
separately in low-adherent 96-well culture plates containing DMEM:Ham’s F-12 
medium supplemented with B27 and 20 ng/mL EGF and bFGF. Cells were plated at a 
density of 50 cells/well and allowed to growth indefinitely with medium and 
supplement refreshment each 2.5 days. As it is shown in Figure 38, both SP and non-SP 
cells give rise to mammospheres. In fact, the number of mammospheres originated from 
non-SP cells was similar to that derived from SP cells, indicating thus that SP fraction 
in MCF-7 cells is not enriched in cells with stem properties. 
 
The second group of cells was used to assess tumorigenicity in an in vivo orthotopic 
model of breast cancer. With this aim, 200 SP or non-SP cells were injected into the 
fourth mammary fat pad of 6-week-old virgin nu/nu female mice (n=6) that had 
received oestrogen implementation before. Tumour apparition was checked daily by 
palpation and tumour volume was measured with a caliper thrice a week. As it can be 
observed in Figure 39 both SP and non-SP cells gave rise to detectable tumours at 
approximately 15 days after inoculation, and tumour burden followed a similar 
progression in both groups, indicating similar tumorigenicity in vivo for SP and non-SP 
cells. 
Figure 38. Mammosphere-forming potential of SP and Non-SP cells. 
MCF-7 cells stained with Hoechst 33342 were analyzed by flow cytometry to determine the SP 
region. Both cells in the SP region and cells in a non-SP region were sorted  and  seeded in non-
adherent plates at a density of 50 cells/well. Mammosphere formation was evaluated by direct 
observation. Non-SP cells, as well as SP cells, formed spheres. Images were taken 10 days after cell 
sorting. Scale bar, 200 μM 
104 
 
 
Altogether, these results indicate that PPARγ ligands significantly reduce growth and 
self-renewal of breast cancer stem cells. At the same time our findings disqualify 
screening for the CD44+/CD24-/low phenotype and SP sorting as methods for direct 
isolation of cancer stem cells, at least in the cell lines analyzed in this study. 
 
Figure 39. In vivo tumorigenicity of SP and non-SP cells. 
Measurement of tumour burden in nu/nu female mice inoculated orthotopically with SP or non-SP 
human breast cancer cells. Results show means value ± SD. 
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DISCUSSION 
Cancer is a multifactorial disease resulting from deregulation of cell proliferation and 
cell death; two processes strictly regulated as they constitute the basis for the correct 
tissue architecture and physiology, and, therefore, for the adequate performance of an 
organism. Under normal circumstances this balance is maintained by processes of 
opposing outcome, such as proliferation, differentiation and programmed cell death. 
However, when cells escape the control of mitogenic signals and become capable of 
growing independently, are incapable of evolving towards a differentiated phenotype or 
avoid apoptotic processes, the equilibrium is disrupted and the cell behaves no more as 
part of an organism but as an individual, giving rise to the apparition of a tumour. 
 
Currently, cancer is the second leading cause of death after cardiovascular disease. 
Thus, the discover of therapies that efficiently suppress tumour growth or cause its 
complete involution is a main objective in the actual medical horizon. During the last 
years PPARγ ligands have been shown not only to be effective in the treatment of type 
II diabetes or inflammation, but also to have a potent anti-tumorigenic effect in several 
types of carcinomas. Nowadays, it is widely accepted that activation of the receptor 
PPARγ inhibits tumour cell growth, promotes differentiation and induces apoptosis. The 
anti-tumoral effects of PPARγ ligands are exerted not only through activation of this 
receptor but also as a result of interactions with other proteins within the cell.  
 
Our work has focused on the elucidation of the antitumorigenic effects and mechanism 
of action of PPARγ ligands in human breast cancer cells, both in the bulk population of 
the tumour and in the cancer stem cell subset. 
 
1.- EFFECT OF PPARγ LIGANDS ON THE GROWTH OF HUMAN 
MAMMARY CANCER CELLS. 
Previous studies from our lab indicated that PPARγ ligands exert antiproliferative and 
proapoptotic effects on human breast cancer cells (Pignatelli et al., 2003; Pignatelli et 
al., 2001; Pignatelli et al., 2005). To further corroborate this we have performed a 
complete study on cell viability, proliferation and apoptosis with three PPARγ ligands 
of known antineoplastic capacity: 15-deoxi-Δ12,14-PGJ2 (15d-PGJ2), rosiglitazone (RSG) 
and pioglitazone (PGZ). 
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In agreement with previous data, 15d-PGJ2, rosiglitazone and pioglitazone cause a 
reduction in viability of SKBR3, MCF-7, T47D and MDA-MB-231 cells. However, the 
extent of the effect on cell viability varies along these PPARγ ligands. Thus, 15d-PGJ2 
provokes drastic levels of cell death rapidly, whereas the effects of rosiglitazone and 
pioglitazone, although significant, are not so pronounced at short times. This raises the 
possibility that each agonist is acting through different mechanisms. In fact, 15d-PGJ2 
has been reported to induce cell death through pleiotropic mechanisms (Pignatelli et al., 
2005), in which PPARγ activation is not a compulsory requirement (Clay et al., 2002). 
In addition, reduced cell viability after treatment with PPARγ ligands is accompanied 
by decreased cell proliferation and increased apoptosis of breast cancer cells. Similar 
effects have been reported after treatment with this compounds in a wide range of cell 
types, including prostate carcinoma, colon carcinoma, lung cancer and glioma 
(Grommes et al., 2004). 
 
Moreover, our work identifies members of the thiadiazolidinones (TDZDs) family of 
compounds, such as TDZD-8 and NP031122 as compounds with antitumorigenic 
activity in breast cancer cells. Treatment of human breast cancer cells with these agents 
caused a reduction in cell proliferation, viability and clonogenicity. Moreover, our data 
suggest that these effects could be mediated by PPARγ activation, since our results 
demonstrate that TDZD-8 efficiently activates transcription of a PPARγ-response 
construct. This is in agreement with previous data from our laboratory indicating that 
TDZDs effects are mediated by PPARγ (Luna-Medina et al., 2005; Luna-Medina et al., 
2007). Interestingly, several members of the TDZD family had been reported to date to 
exert cytoprotective effects in brain tissue, and thus our findings indicate that these 
compounds exert different effects in normal and cancer cells. Accordingly, recent 
evidence indicate that TDZD-8 is a potent inductor of cell death in leukaemia stem 
cells, with significant cell death observed as soon as 2 hours after addition of TDZD-8. 
Taking into account that these compounds are known inhibitors of GSK-3β, our 
findings open the possibility of an alternative mechanism of action of the members of 
the family of the TDZDs mediated by PPARγ instead of, or in cooperation with, 
inhibition of GSK-3β. 
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2.- BLOCKADE OF PROLIFERATIVE SIGNAL TRANSDUCTION 
PATHWAYS TRIGGERED BY ErbB RECEPTORS. 
Our work identifies SHP-1 phosphatase as an effector of ErbB receptors 
dephosphorylation in response to 15d-PGJ2 treatment in breast cancer cells. Previous 
studies of our laboratory indicate that dephosphorylation of ErbB2 and ErbB3 causes 
their inactivation and subsequent blockade of MAPK and PI3K pathways, leading to a 
reduction in cell survival and proliferation (Pignatelli et al., 2001). In agreement with 
this, SHP-1 has been shown to have a negative role in regulating proliferation of several 
types of cancers. Thus, knock-out mice lacking expression of SHP-1 show 
hyperproliferation of hematopoietic cells in response to growth factor stimulation. 
Moreover, SHP1 protein is decreased in most of the highly aggressive lymphoma and 
leukaemia cell lines (Oka et al., 2001). Together, these findings strongly suggest a 
negative regulatory role for SHP-1 in cell proliferation induced by growth factors. 
 
Moreover, SHP-1 has been previously implicated as a negative mediator in receptor 
tyrosine kinase signalling pathways. Among others, SHP-1 has been previously reported 
to negatively regulate C-kit (Paulson et al., 1996), colony-stimulating factor-1 receptor (Chen 
et al., 1996) and Lck (Lorenz et al., 1996) and cytokine receptors such as erythropoietin receptor 
(Klingmuller et al., 1995) and interleukin-3-receptor (Yi et al., 1993). In fact, SHP-1 is known 
to interact and dephosphorylate EGFR signalling pathway in several cancer cell lines, 
including MCF-7 cells (Tomic et al., 1995). SHP-1 binds EGFR via its two SH2 
domains and dephosphorylates the receptor (Tenev et al., 1997). EGFR, in turn, is 
capable of phosphorylating SHP-1 increasing its activity and promoting its recruitment 
to the receptor (Keilhack et al., 1998). Interestingly, although SHP-1 has been reported 
to interact with EGFR in MCF-7 cells and results from other groups point to a close 
relationship between EGFR and SHP-1, no changes in EGFR phosphorylation were 
observable upon treatment with 15d-PGJ2 (Pignatelli et al., 2001). However, EGFR is 
not the only member of the ErbB family that has been related with SHP-1. SHP-1 has 
also been found to be capable of binding to a chimeric ErbB2 receptor in vitro (Vogel et 
al., 1993). Moreover, SHP-1 dephosphorylates the chimeric ErbB2. With regard to this, 
our data indicate association of SHP-1 with both ErbB2 and ErbB3, although 
immunoprecipitation studies indicate that the amount of phosphatase bound to each 
receptor remains unaltered after 15d-PGJ2 treatment.  
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Although no changes in total SHP-1 protein or mRNA content were observable upon 
15d-PGJ2 treatment, a shift in the electrophoretic mobility of the protein occurred. This 
shift was confirmed by immunoprecipitation studies to be caused by phosphorylation of 
the phosphatase. SHP-1 becomes active upon tyrosine phosphorylation by several 
receptors. The insulin receptor, for example, phosphorylates SHP-1 on Tyr536 (Uchida 
et al., 1994) and nerve growth factor receptor, Lck and Src are also able to 
phosphorylate SHP-1, leading to an increase in its activity in vitro (Frank et al., 2004; 
Vambutas et al., 1995). SHP-1 exists in a closed, autoinhibited conformation with the 
N-terminal SH2 domain occupying the catalytic region of the phosphase. Binding of the 
C-terminal SH2 domain to a phosphotyrosine residue in the target protein together with 
phosphoylation of the phosphatase induces a conformational change in SHP-1 that 
results in the release of the autoinhibition (Yang et al., 2003). Two major 
phosphorylation sites at tyrosines 536 and 554 have been reported to cause SHP-1 
activation. Accordingly, our data show that phosphorylation of SHP-1 in response to 
15d-PGJ2 is correlated with an increase in its phosphatase activity, that would be 
responsible for dephosphorylating ErbB2 and ErbB3. This statement is further 
supported by the fact that overexpression of SHP-1 in MCF-7 cells partially reverts 
ErbB2 and ErbB3 NRG-induced phosphorylation. Moreover, we report that 
dephosphorylation of ErbB2 in response to 15d-PGJ2 is not completely abolished by 
reduction of SHP-1 protein. As we were not able to completely knock-out SHP-1 by 
iRNA strategy, we do not know whether this finding is due to either the activity of the 
remaining SHP-1 or additional tyrosine phosphatases, which could contribute to 
dephosphorylate ErbB2/3 in 15d-PGJ2-treated breast cancer cells.  
 
Interestingly, the observed increase in SHP-1 activity is not sustained in time but 
transient. Short-lasting signals are common regulatory mechanisms of cell signalling 
cascades, especially in the case of switch-on/off regulation. By being transiently 
activated during a short period of time, the cell obtains an on/off mechanism that allows 
a fast and sharp regulation of cell signaling processes. In line with this, SHP-1 is known 
to possess the capacity to autodephosphorylate, loosing then its activity. This could 
explain the limited duration of the observed increase in SHP-1 phosphorylation and 
activity reported in our work.  
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Our data do not clarify the biochemical mechanism by which, upon treatment with 15d-
PGJ2, SHP-1 causes dephosphorylation of ErbB2/ErbB3. Although we do not know yet 
whether this effect is direct or indirect via adapter proteins, studies are now in progress 
to specifically address this issue. Nonetheless, identification of SHP-1 as the mediator 
of ErbB2 and ErbB3 dephosphorylation gives a new insight in the regulation of ErbB 
signalling and serves as basis for an interesting discussion on ErbB signalling network. 
Recent studies suggest that SHP-2 could play a role in ErbB2 signalling regulation 
antagonizing the one we propose for SHP-1. According to these studies, SHP-2 
inhibition in ErbB2-containing breast cancer cell lines abolishes mitogenic and pro-
survival signalling cascades at the same time that reverts transformation  (Zhou and 
Agazie, 2008). This would be due to active SHP-2 promoting Ras activation by 
blockade of its down-regulator Ras-GTPase activating protein (Ras-GAP). This opens 
the possibility of a possible countermeasure mechanism between SHP-1 and SHP-2 in 
vivo that would regulate the proliferative output of the cell.  
 
Figure 1. Proposed action of SHP-1 on ErbB2/ErbB3 signalling pathway. 
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These data demonstrate that responsiveness to 15d-PGJ2 in breast cancer cells is 
partially mediated by SHP-1 phosphatase activity. Therefore, the effects of this 
prostanoid on cell proliferation and survival are dependent on SHP-1 activation status, 
since this determines ErbB2/ErbB3 phosphorylation and subsequent activation of PI3K 
and MAPK signalling pathways.  
 
3.- INDUCTION OF MITOTIC ARREST AND CYTOSKELETON 
DYSRUPTION. 
In this work, we also present evidence of other possible mechanism through which 15d-
PGJ2 could affect proliferation and cell death of breast cancer cells. We show that cell 
death induced by 15d-PGJ2 in human MCF-7 cells is preceded by a marked G2/M arrest. 
The cells also displayed morphological features that identified a mitotic arrest, 
specifically in metaphase. Our studies also show that 15d-PGJ2 binds to microtubules, 
forming a covalent bond with several cysteine residues in α- and β-tubulin. Overall 
these results point to a role of 15d-PGJ2 in breast cancer cells independent of PPARγ 
activation and involving a direct binding to tubulin and posterior disruption of 
microtubules. This idea is further substantiated by the fact that these effects are not 
observed in rosiglitazone-treated MCF-7 cells.  
We have previously demonstrated that 15d-PGJ2 inhibits proliferation and induces 
cellular differentiation and apoptosis in the breast cancer cell line MCF-7, in part by 
blocking the ErbB receptor signalling pathway (Pignatelli et al., 2001) and by inducing 
early mitochondrial alterations (Pignatelli et al., 2005). Our results suggest that the 
effects of 15d-PGJ2 can be both dependent and independent of PPARγ activation 
(Martinez et al., 2005; Pignatelli et al., 2003; Pignatelli et al., 2005). This is in 
accordance with the description by other groups of PPARγ-independent pleiotropic 
effects of 15d-PGJ2 responsible for its antiproliferative activity (Chaffer et al., 2006; 
Kim et al., 2008). Although 15d-PGJ2 is a potent PPARγ activator, an important part of 
the effects exerted by this compound have been proved to be independent of the 
activation of PPARγ. Thus, 15d-PGJ2 has been shown, for example, to induce apoptosis 
of breast cancer cells (Clay et al., 2002) and inhibit microglial activation (Phulwani et 
al., 2006) independently of PPARγ. Our data also indicated a possible involvement of 
the cytoskeleton in the antiproliferative effect of 15d-PGJ2 (Pignatelli et al., 2005). 
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Consistent with this idea, in this study we demonstrate that 15d-PGJ2 treatment of 
MCF-7 cells causes extensive microtubule (MT) depolymerization and disruption of the 
MT network in interphase cells, similar to the one observed in cells treated with 
nocodazole. This effect is probably due to the observed in vitro and in vivo binding of 
15d-PGJ2 to, both α- and β-tubulin subunits.  
Our work reveals that 15d-PGJ2 profoundly affects cell division, since treatment with 
this prostanoid alters the centrosome pattern of MCF-7 cells. Centrosomes 
abnormalities are hallmarks of various cancers and are found in essentially all high-
grade cancers and in cell lines derived from tumors (Badano et al., 2005; Pihan et al., 
1998; Pihan et al., 2001; Sankaran and Parvin, 2006; Schneeweiss et al., 2003; Srsen 
and Merdes, 2006). These anomalies are usually associated with an increase in 
pericentrin staining and the appearance of clusters of pericentrin staining material, 
which may represent multiple centrosomes clumped together at a single pole or an 
inappropriate accumulation of pericentrin. On the contrary, non-tumor tissues present a 
low level of diffuse staining, probably reflecting the modest level of cytoplasmic 
pericentrin present in normal cells, or a single discrete focus of pericentrin (Pihan et al., 
1998). Our results show that, in the presence of 15d-PGJ2, MCF-7 cells exhibited fewer 
pericentrin foci and pericentrin staining was considerable lower than in non-treated 
cells. Also, the abnormal large aggregates of pericentrin seen in control MCF-7 cells, 
were not observed in 15d-PGJ2-treated cells, indicative of a less transformed phenotype. 
Our findings also show arrest of 15d-PGJ2-treated MCF-7 cells in G2/M phase of the 
cell cycle. This ability of 15d-PGJ2 to block MCF-7 cells in G2/M phase is consistent 
with a disruption of cytoskeleton via binding to tubulin (Schneider et al., 2003). Among 
novel drugs for the treatment of breast cancer are those that target microtubules. These 
drugs suppress MT dynamics and trigger mitotic arrest at the metaphase/anaphase 
transition (Jordan, 2002; Wilson and Jordan, 1995). In the presence of these drugs, 
spindle form and mitosis can progress as far as the metaphase/anaphase transition. 
However, the spindles are unable to pass the mitotic checkpoint and to initiate anaphase, 
or do so only after a long period of mitotic arrest. In agreement with this, our results 
show that 15d-PGJ2 completely blocks the transition to anaphase. Only a few cells 
appear to enter the anaphase state but they are unable to complete the segregation of the 
chromosomes and eventually return to a “metaphase-like” stage afterward they die. 
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Regarding this point, there is compelling evidence indicating that mitotic arrest caused 
by tubulin-binding agents such as paclitaxel and the vinca alkaloids is frequently found 
to precede apoptosis of cancer cells (Jordan, 2002; Lin et al., 1998). Thus, the 
hypothesis that arrest of the cell cycle at mitosis is the primary stimulus for apoptosis 
has been widely accepted. For example, apoptosis induced by paclitaxel was found to 
occur directly after a mitotic arrest or after an aberrant mitotic exit (Jordan et al., 1996; 
Woods et al., 1995). Nevertheless, some investigators have provided evidence against 
the involvement of mitotic arrest in apoptosis induction by microtubule-binding agents 
by demonstrating apoptotic events in other phases of the cell cycle (Huang et al., 2000; 
Miller et al., 1999). Apoptosis is not the only mechanism by which cells die following a 
failed mitosis. Many studies have described a form of cell death called mitotic 
catastrophe. This form of cell death does not require caspase 9 or 3 and can still occur in 
the presence of caspase inhibitors such as z-VAD-fmk. In this regard, previous work 
from our laboratory have shown that the cell death induced by 15d-PGJ2 in breast 
cancer cells cannot be completely inhibited by treatment with this caspase inhibitor, 
albeit caspases are activated in MCF-7 cells treated with this prostaglandin (Pignatelli et 
al., 2005). On the other hand, we could not observe any of the common features 
attributed to mitotic catastrophe, such as giant non-viable multinucleated cells. 15d-
PGJ2-arrested mitotic MCF-7 cells appear to remain arrested in metaphase from which 
they subsequently entered a cell death pathway without exiting mitosis. This 
phenomenon has been previously shown in endothelial cells treated with the tubulin-
binding agent combretastin A-4-phosphate (Kanthou et al., 2004; Nabha et al., 2002). 
These authors have shown that combretastin A-4-phosphate damages mitotic spindles, 
arrests cells at metaphase, and leads to the death of endothelial mitotic cells with 
characteristic G2/M DNA content. 
Furthermore, our results obtained from mass spectrometry (MS) analyses demonstrated 
that 15d-PGJ2 binds covalently to tubulin and that this binding is the cause of 
microtubule depolymerization in 15d-PGJ2-treated MCF-7 cells. Our findings show that 
15d-PGJ2 binds covalently to at least, four cysteine residues into the α- and β-tubulin 
moieties, as detected by MS. 15d-PGJ2 is characterized by the presence of a 
cyclopentenone ring containing an electrophilic carbon (C9), and an electrophilic 
unsaturated carbonyl group (C13) next to the cyclopentenone ring. These two reactive 
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centers can react covalently by means of Michael’s addition reaction with nucleophiles, 
such as the cysteinyl thiol groups in proteins, to form a covalent adduct which is 
thought to be irreversible under physiological conditions. Some examples of 15d-PGJ2 
Michael’s addition to cysteine residues include PPARγ (reactive carbon at position 13) 
and NF-κB (reactive carbon at position 9) proteins (Kim and Surh, 2006).  
Tubulin is a heterodimeric protein containing 20 cysteine residues, of which twelve are 
in the α subunit and eight in the β subunit. Five of these cysteines have been 
characterized as highly reactive (Britto et al., 2002). We have shown here that, at least 
four of them react with 15d-PGJ2. Cysteine 305 from β-tubulin is located on the surface 
of the MT near the pore, and probably does not have any effect on MT stability. In 
contrast, cysteines 241 and 356 are located at the inner face, between the GTP and the 
taxol binding sites, and the binding of 15d-PGJ2 to these residues could alter the normal 
curvature of the heterodimer, inducing MT depolymerization. In addition, cysteine 316 
from α-tubulin is located in the interphase between an α-subunit and a β-subunit, and, 
consequently, it is very likely that 15d-PGJ2-binding to this residue could also interfere 
in the microtubule assembly. Thus, covalent binding of 15d-PGJ2 to cysteine residues in 
microtubules is probably the cause of the observed microtubules depolymerization. 
 
Figure 2. Identified binding sites for 15-deoxi-Δ12,14-PGJ2 in α- and β-tubulin. 
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Summarizing these data, the described effects of 15d-PGJ2 on cytoskeleton add a new 
anti-tumoral role for 15d-PGJ2 based on the ability to directly binding to cysteine 
residues in α- and β-tubulin independently of PPARγ. As a consequence, 15d-PGJ2 
disrupts the MT structure in the cytoplasm of interphase cells and the spindle apparatus 
of mitotic cells leading to a mitotic arrest at the metaphase/anaphase transition, an 
accumulation of cells in G2/M phase, and ultimately breast cancer cell death. 
 
4.- EFFECT OF PPARγ LIGANDS ON HUMAN BREAST CANCER STEM 
CELLS. 
Cancer stem cells (CSCs) have been recently identified in leukaemia, and they are 
intensively searched in different solid tumours. The culture under non-adherent 
conditions and the utilization of cell surface expression markers has made possible their 
isolation from brain tissue, and therefore this strategy is being used for prospective 
isolation from other tissues such as breast, colon or pancreas, where neither the surface 
antigens nor the expression pattern characterizing the subset of CSCs have been well 
defined yet.  
 
Our results indicate that all of the four cell lines tested (SKBR3, MCF-7, T47D and 
MDA-MB-231) were able to form mammospheres when grown under non-adherent 
conditions. Non-adherent culture is a widely accepted method to determine the 
existence of stem cells in mammary tissues. Strong evidence support that single stem 
cells from normal human mammary tissue, when grown under non-adherent conditions, 
originate spheres capable of generating the three lineages that constitute the tissues in 
the mammary gland: myoepithelial, luminal and acinar (Dontu et al., 2003). This 
property of mammary stem cells to originate spheres is not restricted to normal stem 
cells, but shared with cancer stem cells (Fillmore and Kuperwasser, 2008). 
Consequently, the fact that all cell lines give rise to the formation of mammospheres 
implies that cancer stem cells exists in SKBR3, MCF-7, T47D and MDA-MB-231 cell 
lines. Considering the number of spheres generated with the number of cells cultured, 
we conclude that cancer stem cells in these cell lines constitute approximately ≤1% of 
total population, even though frequency varies depending on the cell line. This 
frequency is in agreement with previous data reporting stem cells to be scarce, with 
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percentages lower than 1% of the whole cell population (Bonnet and Dick, 1997). Our 
results are further supported by similar observations by other groups, that describe stem-
like properties in the cells composing mammospheres derived from MCF-7 cell line 
(Ponti et al., 2005). 
 
Remarkably, our data demonstrate that PPARγ ligands significantly reduce cancer stem 
cell growth, since treatment with these compounds significantly diminish the number of 
spheres, with 15d-PGJ2 and rosiglitazone showing the most significant effects. 
However, effects exerted by pioglitazone, although not so rapidly also cause a decrease 
in mammosphere number, and moreover, impairs self-renewal of cancer stem cells. 
Thus, the previously mentioned antineoplastic effects of PPARγ ligands are not limited 
to cells of the bulk of the tumour, but are also effective on the cancer stem cell subset. 
 
In addition, the present study analyzes the reliability of other systems rather than 
mammosphere culture to study breast cancer stem cells. Although mammosphere 
formation is a widely accepted method to identify cancer stem cells, it accounts for the 
disadvantage of being an indirect method that indicates the presence of a cancer stem 
cells only after it has undergone division and formed a cluster of daughter cells 
composed by both stem and differentiated cells. Thus, although this method enormously 
purifies the culture in cancer stem cells, it is not capable of identifying single cancer 
stem cells, rending impossible their isolation. To this purpose, characterization of 
cancer stem cells by differential expression of membrane antigens has become a 
priority. 
 
Serial dilution transplantation studies in immunocompromised mice established 
CD44+/CD24-/low expression pattern as the defining-phenotype for breast cancer stem 
cells (Al-Hajj et al., 2003). However, our screening for this phenotype in human breast 
cancer cell lines revealed that SKBR3, MCF-7 and T47D cells are depleted of cells with 
this pattern, whereas MDA-MB-231 cells are nearly 100% positive for this profile. This 
data are in agreement with data from other authors. Sheridan et al. obtained similar 
percentages of CD44+/CD24-/low cells in the four cell lines studied (Sheridan et al., 
2006), and recently Crocker et al. reported similar percentages in MCF-7 (0.05 ± 
0.01%) and MDA-MB-231 (79 ± 2.7%) cells (Croker et al., 2008). In addition, our 
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analysis by flow cytometry for CD44 and CD24 staining reveals that there is no 
enrichment in CD44+/CD24-/low cells in mammospheres when compared to adherent 
cultures. However, culture as spheres has been shown to result in increased number of 
progenitor cells (Dontu et al., 2003). Therefore, our flow cytometry results opposed 
those obtained from the mammosphere-forming assays, that had revealed the existence 
on cancer stem cells in all four cell lines. Interestingly, SKBR3, MCF-7 and T47D share 
a common origin. These cell lines are derived from luminal tissue in the mammary 
gland, whereas MDA-MB-231 cells have a basal origin, suggesting that CD44+/CD24-
/low profile could be a marker for basal origin, instead of stemness. This conclusion is 
further supported by the fact that no statistical significance has been found for CD44 
nor CD24 with any histopathologic characteristic (such as grade, size or type) in 
primary breast tumours (Abraham et al., 2005). Moreover, a study regarding 240 human 
breast primary tumours detected CD44+/CD24-/low cells only in 31% of the tumours, the 
majority of which were of basal origin (Honeth et al., 2008). In addition, no correlation 
between CD44+/CD24-/low profile and prognosis (Shipitsin et al., 2007) or metastatic 
capacity (Sheridan et al., 2006) has been found, whereas evidences correlating CD24 
staining and luminal origin in normal mouse mammary gland cells (Sleeman et al., 
2006) have been published. According to this, CD24- cells correspond to non-epithelial 
cells, whereas CD24low cells are myoepithelial and CD24hi are luminal.  
 
The activity of the enzyme aldehyde dehydrogenase (ALDH) has been shown to 
identify cells with stem properties in several tissues, including breast and colon 
(Ginestier et al., 2007). However, the utilization of this marker in our studies in 
unviable due to the fact that ALDH gene expression has been reported to be upregulated 
by PPARγ ligands (Moreb et al., 2008), and the utilization of this marker would 
therefore bias our results.  
 
Other authors consider the side population (SP) a model of cancer stem cells (Zhou et 
al., 2007) based on the observations that this population is enriched in tumorigenic 
stem-like cancer cells (Patrawala et al., 2005). However, the same authors state that 
tumorigenicity is not dependent on expression of the ABCG2 transporter, in charge of 
mediating the efflux of Hoechst 33342 that determines the apparition of the SP. 
Moreover, murine mammary stem cell have not been found to be preferentially in the 
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SP region (Stingl et al., 2006). We report that PPARγ ligands, which we prove to 
seriously affect growth of cancer stem cells, have no effect on the percentage of cells 
comprising the SP of MCF-7 cells. In addition, we conclude that SP is not a reliable 
model of cancer stem cells, since both cells in the SP and their non-SP counterparts are 
capable of originating spheres and exhibit similar tumorigenicity in vivo. Although there 
are evidences in several cancer types pointing to greater SP tumorigenity, several 
findings indicate that SP cells are capable of a better growth than non-SP cells at low 
density (Mitsutake et al., 2007). 
 
Altogether, our work provides evidence that PPARγ ligands exert antiproliferative 
effects on human breast cancer stem cells throughout multiple mechanism including 
regulation of cancer stem cells.  
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CONCLUSIONS  
 
 
1.- 15-deoxi-Δ12-14-Prostaglandin J2, rosiglitazone and pioglitazone cause a decrease 
in the viability of human breast cancer cells, together with a reduction of their 
proliferation and an increase in their apoptosis.  
 
2.- Members of the thiadiazolidinones (TDZDs) family are efficient inducers of 
breast cancer cell death, causing a decrease in their viability and proliferation 
through a mechanism that possibly implies PPARγ activation. 
 
3.- Src-Homology-2 domain-containing phosphatase 1 (SHP-1) mediates the 
dephosphorylation of ErbB2 and ErbB3 receptors in response to treatment with 
15d- Δ12-14-Prostaglandin J2, causing a blockage of their signalling pathway. 
 
4.- 15-deoxi-Δ12-14-Prostaglandin J2 induces cell cycle arrest in the G2/M phase of 
the cell cycle and disruption of the microtubule network due to direct binding of 
this prostanoid to α- and β-tubulin and a subsequent mitotic arrest.  
 
5.- 15-deoxi-Δ12-14-Prostaglandin J2, rosiglitazone and pioglitazone significantly 
inhibit cell growth and self-renewal of human breast cancer stem cells. 
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CONCLUSIONES  
 
 
1.- 15-deoxi-Δ12-14-Prostaglandina J2, rosiglitazona y pioglitazona causan una 
reducción de la viabilidad de células humanas de cáncer de mama así como a 
una reducción de su proliferación y un aumento de su apoptosis. 
 
2.- Los miembros de la familia de las tiadiazolidinonas (TDZDs) son eficientes 
promotores de la muerte de células de cáncer de mama, provocando un descenso 
de su viabilidad y proliferación mediante un mecanismo en el que posiblemente 
está implicada la activación de PPARγ. 
 
3.- La fosfatasa 1 con dominios de homología a Src (SHP-1) media la 
defosforilación de los receptores ErbB2 y ErbB3 en respuesta al tratamiento con 
15-deoxi-Δ12-14-Prostaglandina J2, causando el bloqueo de sus respectivas vías 
de señalización. 
 
4.- 15-deoxi-Δ12-14-Prostaglandina J2 promueve la parada del ciclo celular en fase 
G2/M, así como la desestructuración de la red de microtúbulos debido a la unión 
directa de este prostanoide a α- y β-tubulina y la consecuente parada mitótica.  
 
5.- 15-deoxi-Δ12-14-Prostaglandina J2, rosiglitazona y pioglitazona inhiben 
significativamente el crecimiento celular y la auto-renovación de células madre 
humanas de cáncer de mama. 
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